Stockwinners Market Radar for November 13, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:57 EST Hepion Pharmaceuticals announces reduction in liver stiffness with rencofilstat - Hepion Pharmaceuticals announced additional efficacy data for rencofilstat, its lead drug candidate. Additional rencofilstat efficacy data from Hepion's 'ALTITUDE-NASH' clinical trial was presented earlier this afternoon by Dr. Mayo in a late-breaker poster presentation at the Liver Meeting 2023, hosted by the American Association for the Study of Liver Diseases ("AASLD"). Dr. Mayo's presentation indicated that 17 weeks of rencofilstat treatment was associated with significant reduction in liver stiffness (FibroScan) in MASH subjects with advanced F3, an outcome suggesting reduction in hepatic fibro-inflammation. Ongoing hepatic fibro-inflammation leads to progressive accumulation of collagen or fibrosis, increasing liver stiffness, and functional deterioration. Determination of liver stiffness often utilizes an ultrasound-based imaging technique called vibration-controlled transient elastography ("VCTE") of which FibroScan is the most common platform. Physicians rely on liver stiffness measurements as a diagnostic tool to help determine whether liver health is worsening or improving, as the measurements correlate well with the extent of fibrosis in liver biopsies and are predictive of the course of disease. The predictive power of liver stiffness measurements on the course of disease is further enhanced when taken together with blood-based markers of liver disease. Liver stiffness measurements are expressed in kilopascals (kPa), and Fibroscan scores higher than 12 kPa usually represent advanced forms of fibrosis (F3 or F4 in biopsies). Reduction in liver stiffness by rencofilstat likely indicates reduction in fibroinflammation, and reduction in risk for subsequent clinical outcome.

19:50 EST Xyratex Ltd. trading halted, news pending

19:50 EST Tingo Group Inc trading halted, news pending

18:22 EST Strattec Security announces retirement of CEO Frank Krejci and succession plan - Strattec Security announced that Frank J. Krejci, President and CEO will retire from employment with the Company effective December 31. He will also retire from the Company's Board of Directors on December 31st. Rolando Guillot, Senior Vice President - Operations and COO, has been named to serve as Interim CEO, effective January 1, 2024 in addition to his current role. Guillot joined STRATTEC in 1996 and gained experience in various management roles, primarily in STRATTEC's Mexican subsidiary, until September, 2004 when he was elected Vice President - Mexican Operations. In December 2016 he was elected Senior Vice President - Operations, responsible for all the Company's operations, and was elected to his current position in March. The Company will engage a leading national executive search firm to conduct a formal search to identify a successor to Krejci as soon as possible. The Board of Directors is confident that Guillot has the necessary skills and experience to lead STRATTEC while a select group of independent members of the Board conduct the executive search for a successor CEO.

18:02 EST COPT Defense Properties appoints Britt Snider as COO - COPT Defense Properties (CDP) announces the appointment of Britt A. Snider as Executive Vice President and COO, effective December 1. Snider is an established commercial real estate executive with nearly 20 years of experience in development, asset management, property management and leasing, corporate operations, and corporate strategy. Prior to joining COPT Defense, he served as Principal of Redbrick LMD, a diversified real estate investment and development company based in Washington, D.C., where he was a member of the senior leadership team overseeing the company's development, asset management and leasing activities. Prior to Redbrick, Snider served as Senior Vice President at WS Development, a real estate investment and development company based in Chestnut Hill, Massachusetts, where he led the company's mixed-use development initiatives outside of the Boston Seaport. Between 2006 and 2019, Snider served as Executive Vice President, Head of Commercial Asset Management and Principal, Development at JBG Smith (JBGS), a mixed-use investment and development real estate investment trust, where he oversaw the company's office portfolio and development activities.

18:01 EST Vital Energy promotes Katie Hill to COO - Vital Energy announced the promotion of Katie Hill to senior VP and COO, effective November 13. Hill has been with Vital Energy since September 2022 and previously served as VP -Operations.

18:00 EST Coty raises share repurchase program by $600M - Coty announced that its Board of Directors has increased its share repurchase program authorization by an additional $600M to a total availability of approximately $1B. In connection with today's announcement, Coty is entering into total return swaps in respect of its Class A Common Stock with several banks to hedge its potential exposure to prevailing stock price trading levels over the applicable hedging periods for a planned share buyback of approximately 25M shares in fiscal 2026. These agreements are in addition to the Company's previously announced hedge transactions for planned buyback of 27M shares in 3Q FY24 and 23 million shares in FY25. Similar to the initial hedge transactions executed in June and December 2022, any total return swap settled in shares would be covered by the Company's share repurchase authorization. The three hedge transactions are part of Coty's target to reduce its diluted share count toward 800M by FY26. Coty anticipates continued strong free cash flow generation and to achieve steady deleveraging with target leverage of approximately 3x exiting CY23, approximately 2.5x exiting CY24 and approximately 2x exiting CY25.

17:49 EST SunLink Health Systems to sell Trace Regional Medical Center - SunLink Health Systems announced that its subsidiary, Crown Healthcare Investments, has signed an agreement with Progressive Health Group for the sale of the subsidiary that owns and operates Trace Regional Medical Center, which includes a hospital, skilled nursing facility and three patient clinics in Chickasaw County, MS, for approximately $8M. The sale is subject to, among other things, the Buyer's satisfactory completion of its due diligence investigation and a number of customary closing conditions. The company expects to recognize a pre-tax gain of approximately $1.7M on the transaction, which is scheduled to close on December 15. The transaction will therefore be reported in SunLink Health Systems's Q2. The proceeds of the sale of approximately $7.5M after payment of closing costs, will be used for general corporate purposes. As a result of the Company's agreement on November 10, 2023 to sell Trace Regional Medical Center, SunLink Health Systems, Inc. will delay its filing with the SEC of its quarterly report on Form 10-Q for the period ended September 30 which is due by November 14.

17:47 EST Core & Main CFO Witkowski sells $642K in company shares - The CFO of Core & Main Mark Witkowski disclosed the sale of 20,000 shares of company stock at $32.10 per share on November 9 for a total transaction amount of $642,022.

17:10 EST Sun Life Financial increases dividend 3c to 78c - The Board of Directors of Sun Life Financial announced that a dividend of 78c per share on the common shares of the Company has been declared, payable December 29 to shareholders of record at the close of business on November 29. This represents a 3c increase to the amount paid in the previous quarter.

16:58 EST Fisker sees FY23 CapEx $225M-$240M - Sees FY23 Research and Development expenses $160M-$190M and Selling, General, and Administrative $180M-$210M.

16:52 EST IGM Biosciences sees FY23 operating expenses $275M-$285M - The company said, "The Company expects full year 2023 GAAP operating expenses of $275 million to $285 million, including estimated non-cash stock-based compensation expense of approximately $50 million, and full year collaboration revenue of approximately $2 million related to the Sanofi agreement. The Company expects to end 2023 with more than $325 million in cash and investments, and the Company expects its existing cash and investments and anticipated collaboration payments to fund operations into the second half of 2025."

16:35 EST Theseus Pharmaceuticals Inc trading resumes

16:33 EST ConocoPhillips director Leach sells 44,000 common shares - In a regulatory filing, ConocoPhillips director Timothy Leach disclosed the sale of 44,000 common shares of the company on November 9 at a price of $114.6409 per share.

16:21 EST Fidelity National announces intent to invest $250M in F&G Annuities - Fidelity National Financial (FNF) announced its intent to invest approximately $250M in F&G Annuities & Life (FG). FNF held approximately 85% ownership in F&G as of September 30. F&G will use net proceeds from the investment to support the growth of assets under management, as it capitalizes on opportunities in the market. FNF views this as an attractive investment given F&G's current momentum and performance which has exceeded expectations, while still preserving the Company's excess liquidity as a buffer in response to market headwinds and historical low volumes in the Title business. FNF held $949M in cash and short-term liquid investments at the holding company as of September 30. FNF's Board of Directors has formed a Special Committee comprised of independent members of the Board to begin evaluation and negotiation of terms for the investment. FNF's Special Committee will retain an independent financial advisor, as well as legal counsel. The transaction is expected to close in late 2023 or early 2024, subject to customary closing conditions. The Company does not intend to comment on or disclose further developments regarding the Special Committee's work unless and until it deems further disclosure is appropriate or required.

16:18 EST Arthur J. Gallagher acquires Edgar Insurance Brokers - Arthur J. Gallagher & Co. announced the acquisition of Cobram, Victoria-based Edgar Insurance Brokers. Terms of the transaction were not disclosed. Edgar Insurance Brokers provides commercial insurance products and services in Australia with a client focus of rural and farm, hospitality, transport and trades. Shannon Edgar and his team will remain in their current location under the direction of Sarah Lyons, head of retail property/casualty brokerage operations for Gallagher in Australia and Asia.

16:17 EST Tanger Factory announces acquisition of Asheville Outlets in Asheville, NC - Tanger announced that it has acquired its 38th shopping center, Asheville Outlets, as part of the continued execution of the company's external growth strategy. Tanger acquired the center for $70M in an all-cash, off-market transaction, leveraging the company's platform and utilizing its cash holdings and strong balance sheet to create value for all stakeholders. Asheville Outlets is the second fully owned addition to Tanger's outlet portfolio this quarter, following the grand opening of Tanger Outlets Nashville in Tennessee last month.

16:15 EST Azenta announces actions as part of strategic and governance transformation - Azenta announced a series of actions as part of the Company's ongoing strategic and governance transformation. In support of the Company's transformation strategy and as part of its ongoing board refreshment process, Didier Hirsch and Martin Madaus have been nominated for election to its Board of Directors at the Company's 2024 Annual Meeting of Stockholders. Two of the Board's current independent directors will not be nominated to stand for re-election at the Annual Meeting. Following the Annual Meeting - if the new nominees are elected by stockholders - Azenta's Board will continue to be comprised of ten directors, of which nine will be considered independent and seven will have joined the Board since 2018. The Company has embarked on a significant strategic transformation since 2021, including the continued growth of its life sciences business, the sale of its semiconductor automation business in 2022, the implementation of cost reduction initiatives and meaningful capital return to stockholders. In connection with today's announcements, Politan has withdrawn its notice to nominate candidates for election to the Board at the Annual Meeting.

16:15 EST Aecom increases share repurchase authorization, quarterly dividend - AECOM announced that its Board of Directors has approved increases to both its share repurchase authorization to $1B and its quarterly dividend program by 22% to $0.22 per share. The increased share repurchase authorization builds on the $1.8 billion of shares repurchased since September 2020, which has reduced shares outstanding by 19%. "As today's announcement demonstrates, we are committed to our returns-focused capital allocation policy, which is focused on high-returning investments in organic growth followed by returning substantially all available cash flow to shareholders through share repurchases and dividends," said Troy Rudd, AECOM's chief executive officer. "Under this policy, we have delivered highly profitable organic revenue growth, built a record design backlog, and returned $2 billion to shareholders since 2020, which has enhanced our total shareholder return. Our competitive advantages, combined with accelerating end market growth and our strong cash flow and balance sheet, underpin our confidence in long-term shareholder value creation."

16:13 EST Acacia Research acquires majority stake in Benchmark Energy, terms not disclosed - Acacia Research announced that it has acquired a majority interest in Benchmark Energy II, LLC. Headquartered in Austin, TX, Benchmark is an independent oil and gas company engaged in the acquisition, production and development of oil and gas assets in mature resource plays in Texas and Oklahoma. Benchmark is run by an experienced management team led by Chief Executive Officer Kirk Goehring, who previously served as Chief Operating Officer of both Benchmark and Jones Energy, Inc. Benchmark's existing assets consist of over 13,000 net acres primarily located in Roberts and Hemphill Counties in Texas, and an interest in over 125 wells, the majority of which are operated.

16:10 EST Beauty Health CEO Andrew Stanleick to leave company - The BeautyHealth Company announced that Andrew Stanleick will depart the Company as President & Chief Executive Officer and relinquish his Board seat, effective November 19, 2023. Current BeautyHealth Director Marla Beck will serve as Interim Chief Executive Officer while the Company's Board of Directors completes a formal search for a new CEO. "On behalf of the Board of Directors, I would like to thank Andrew for his leadership and commitment to BeautyHealth. He has been a passionate advocate for the Company, especially adding to its visibility within the broader beauty and aesthetics industries through innovative partnerships and thought leadership. We wish him well in all his future endeavors," said Board Chairman Brent Saunders. Stanleick will serve in an advisory role with the Company through the end of the year.

16:09 EST Cara closes financing transaction with HealthCare Royalty extending cash runway - "We are pleased to have closed our non-dilutive financing transaction with HealthCare Royalty, which extends our cash runway into 2025," said Christopher Posner, President and Chief Executive Officer of Cara Therapeutics. "This financing will help us reach key clinical catalysts which we believe will validate the potential of our oral difelikefalin pipeline."Posner continued, "We look forward to releasing topline efficacy and safety data from Part A of our KIND 1 atopic dermatitis trial in December. Our other two late-stage clinical programs for the treatment of pruritus associated with advanced chronic kidney disease and notalgia paresthetica are on track for key data readouts in 2024. We will continue to focus on maintaining a strong balance sheet and delivering on our commitments across our wholly owned pipeline."

16:06 EST ICF International awarded $36M task order by DHS - The U.S. Department of Homeland Security Office of Human Capital recently awarded a new $36M task order to global consulting and technology services provider ICF to modernize the Immigration and Customs Enforcement's (ICE) human resources technology systems. The task order was awarded in Q3 under the Scalable Ways to Implement Flexible Tasks (SWIFT) indefinite-delivery, indefinite-quantity contract, which was awarded to ICF in fall 2022. It has a term of five years, including a one-year base and four one-year option periods.

16:03 EST Air Transport Services delivers Boeing 767-300BCF to My Freighter Cargo Airlines - Air Transport Services Group (ATSG) announced that its subsidiary Airborne Global Leasing has delivered a newly converted Boeing (BA) 767-300 freighter to new customer My Freighter Cargo Airlines of Tashkent, Uzbekistan under the terms of a multi-year lease. "Through its LeasePlus+ service model, ATSG continues to provide unparalleled capacity opportunities to global air cargo customers," said Paul Chase, chief commercial officer of ATSG. "This delivery to My Freighter expands that reach by building capacity in a region recognized for facilitating trade between Europe and East Asia." My Freighter has provided first-class charter air cargo services in Uzbekistan and Central Asia since 2019.

15:11 EST Golden Heaven down 33%, halted after Hindenburg discloses short position - Shares of Golden Heaven Group were down $7.86, or 33%, to $15.89 as of 03:05 PM EST and were halted for volatility after Hindenburg Research disclosed in a tweet that it was short the stock.

14:59 EST Starbucks unionized baristas plan strike on November 16 - Starbucks Workers United stated in a post to the group's website: "Red Cup Day (November 16th) is Starbucks's biggest sales event of the season - and also one of the most infamously hard, understaffed days for the baristas that work them. Last year, workers went on strike. This year, on the heels of victories won by striking workers across different industries nationwide, Starbucks workers are taking the rebellion to the next level! In addition to our nationwide ULP strike on the 16th, we're also asking customers and allies to lead actions at Starbucks stores in their communities in solidarity with workers rising up for a fairer workplace." Reference Link

14:10 EST SQM denies preliminary agreement with Codelco - SQM said in a statement: As of the present date, none of the aforementioned events has transpired, and there the Company has no comments to provide on the matter. The Company also denies the existence of any preliminary agreements, contrary to inaccuracies reported in certain media outlets." Reference Link

13:47 EST Ferrari announces 250 new hires planned in first six months of 2024 - Ferrari announces plans for 250 new hires in the first six months of 2024, half of which should be confirmed in January, and will also launch a series of initiatives to provide even greater support for its people. "A broad-based share ownership plan, a new agreement for the Competitiveness Award signed with the FIM, UILM and FISMIC trade unions, and an expansion of the welfare program are the projects set out today by the company, with the aim of promoting a culture of collective responsibility and increasing engagement in company life," the company stated. Benedetto Vigna, CEO of Ferrari, added: "Ferrari is made of people, who have been, are and will be at the core of our attention. These initiatives demonstrate our desire to foster the sense of belonging that makes us unique, and underline how we continuously strive for excellence."

12:23 EST Golden Heaven Group Holdings Ltd trading resumes

12:02 EST Micromobility.com reports approval for reverse split, expansion of share capital - Micromobility.com announced that shareholders authorized a reverse stock split of the company's issued and outstanding common stock. Upon authorization of the reverse stock split proposal the board of the company's approval for a one-for-one-hundred-fifty reverse split of the company's issued and outstanding shares of common stock became effective which is approved to occur on December 4, 2023, or soon thereafter. This strategic move is designed to optimize the company's capital structure and position it for future growth. Concurrently stockholders authorized an increase in the number of the company's authorized from four hundred million to one billion effective immediately. This substantial expansion of share capital underlines the company's commitment to scaling operations and enhancing shareholder value, paving the way for potential future mergers and acquisitions, and diversifying the business model and revenue streams. Salvatore Palella, Chairman and CEO of micromobility.com Inc., commented on these developments: "The approval of these measures by our shareholders is a strong endorsement of our strategic direction and future prospects. The reverse stock split, together with the increased share capital, are key elements in strengthening our financial foundation and supporting our growth initiatives."

12:01 EST Wolverine World Wide falls -7.5% - Wolverine World Wide is down -7.5%, or -63c to $7.76.

12:01 EST N-able falls -14.3% - N-able is down -14.3%, or -$1.96 to $11.74.

12:00 EST Paragon 28 rises 11.7% - Paragon 28 is up 11.7%, or $1.00 to $9.54.

11:05 EST Joby Aviation announces successful exhibition flight in NYC - Joby Aviation (JOBY) announced that it successfully performed an exhibition flight in New York City yesterday, which it says marks "the first ever electric air taxi flight in the city and the first time Joby has flown in an urban setting." Joby previously announced through its partnership with Delta Air Lines (DAL) that it expects New York to be one of its early launch markets after receiving certification from the Federal Aviation Administration. "Joby has flown more than 30,000 miles with its full-scale prototype eVTOL aircraft, beginning in 2017. The company recently celebrated the first aircraft to roll off its Pilot Production Plant in Marina, California, and delivered the first-ever electric air taxi to the US Air Force for on-base operational testing. Joby expects to launch its commercial passenger service in 2025," the company stated.

10:53 EST DMK Pharmaceuticals reports preclinical results on DPI-125 - DMK Pharmaceuticals announced the presentation of preclinical results comparing the effects of DPI-125 on opioid withdrawal behaviors to methadone and buprenorphine, the standard of care for opioid use disorder, or OUD, in a poster session at the Society for Neuroscience Annual Meeting held November 11-13, 2023 in Washington D.C. "Only about 12% of patients receive treatment for OUD, despite the proven efficacy of current medications. Buprenorphine, the market leader with US sales in excess of $3B in 2022, requires an induction phase to induce withdrawal symptoms prior to initiating the first dose. It is challenging for a patient to voluntarily experience these symptoms. In addition, buprenorphine can be abused. For this and other reasons, widespread adoption is low. We believe that DPI-125, our novel clinical stage compound, will be able to overcome this and several other barriers to treatment initiation and maintenance. The positive data to be presented today marks the first step to realizing this promise. We are excited to present preclinical data comparing DPI-125, a triple opioid agonist, to the standard of care treatments buprenorphine and methadone to alleviate withdrawal symptoms. This preclinical study was financially supported by a grant from the National Institute of Drug Abuse, and we believe that it warrants further development," said Eboo Versi, M.D., Ph.D., CEO of DMK Pharmaceuticals.

10:39 EST FiscalNote announces strategic alliance with True Digital Group - True Digital Group and FiscalNote Holdings announced a strategic alliance to map 3rd and 4th party vendors and monitor critical risks, which they see "presenting a first of its kind opportunity for financial institutions to understand and monitor risks within their expansive supplier networks and elevate transparency throughout the vendor ecosystem." The companies stated: "The partnership leverages the AI-powered, cutting-edge technology and data analytics capabilities of FiscalNote Risk Connector to furnish True Digital and its bank industry members with an invaluable resource for risk management. FiscalNote's state-of-the-art AI models provide a unique view for banks of their vendor's supply chain structure - a strategic advantage that empowers community and regional banks by offering them a solution to better navigate the intricate web of vendor relationships, serving as a pivotal asset in both the vendor selection and ongoing monitoring processes."

10:13 EST B. Riley Financial shares drop to lowest level in three years - B. Riley Financial shares have fallen 22% to $19.76 in early trading. The shares are at an intraday level lower than any close since June 25, 2020, according to data from Bloomberg.

10:03 EST GE HealthCare, BAMF Health collaborate for Theranostics solutions - As demand for Theranostic care increases, GE HealthCare and BAMF Health announced a collaboration aimed at enabling BAMF Health to scale turnkey offerings inclusive of leading GE HealthCare technologies and services. The goal of the collaboration is to ensure an agile go-to-market approach to enhance the adoption of Theranostics solutions in the U.S. The arrangement supports a shared interest in better patient outcomes made possible through advanced diagnostics and radiotherapeutics. Theranostics in molecular imaging uses both imaging technology and targeted therapies to identify and treat diseases such as cancer as well monitor response to treatment; the term originates from the way this form of personalized medicine is practiced - the combination of therapy and diagnostics. Connecting all phases of the Theranostics care pathway, from drug development through disease diagnosis and treatment monitoring, with scalable solutions, connectivity, and advanced imaging technologies, is critical to helping clinicians and health systems bring Theranostics treatments to more patients. The collaboration between GE HealthCare and BAMF Health will leverage both partners' deep understanding of the complexities of delivering Theranostic care to establish a framework to support the scalable infrastructure and clinical solutions for expanded adoption of precision care.

10:01 EST Izea announces IZEA.com has reached the 1 million user milestone - IZEA Worldwide announced that IZEA.com has reached the 1M registered user milestone. In recent months, the company has been adding between 1,000 and 2,000 new registered users per day to IZEA.com. The sharp increase in user signups is largely attributed to the release of FormAI, the company's suite of AI tools for creators and marketers. "We are proud to have reached this important milestone," said Ted Murphy, IZEA founder and CEO. "While there are many claims about network size in the influencer marketing industry, very few have first-party opt-in networks anywhere near that of IZEA, and the network growth we have seen over the past few months has been incredible."

10:00 EST Genius Sports falls -8.7% - Genius Sports is down -8.7%, or -46c to $4.81.

10:00 EST Harmony Gold rises 8.5% - Harmony Gold is up 8.5%, or 38c to $4.85.

10:00 EST Penumbra rises 17.8% - Penumbra is up 17.8%, or $32.34 to $213.78.

09:56 EST Newegg Commerce receives non-compliance notification from Nasdaq - On November 6, 2023, Newegg Commerce received a letter from the Listing Qualifications Department of The Nasdaq Capital Market notifying the Company that it is currently not in compliance with the minimum bid price requirement set forth under Nasdaq Listing Rule 5550(a)(2), because the closing bid price of the Company's common shares was below the minimum of $1.00 per share for a period of 30 consecutive business days. This press release is issued pursuant to Nasdaq Listing Rule 5810(b), which requires prompt disclosure of receipt of a deficiency notification. The notification has no immediate effect on the listing of the Company's common shares, which will continue to trade uninterrupted on Nasdaq under the ticker "NEGG." Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has a compliance period of 180 calendar days, or until May 6, 2024, to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per share of the Company's common shares is at least $1.00 for a minimum of ten consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed. In the event the Company does not regain compliance with the minimum bid price requirement by May 6, 2024, the Company may be eligible for an additional 180-calendar-day grace period.

09:50 EST Buyer consortium urges Hollysys directors to convene Special Meeting - A buyer consortium led by Recco Control Technology and Dazheng Group Investment Holdings Company expressed its strong desire for the Special Committee of the board of directors of Hollysys Automation Technologies to allow the sale process of the Company to move forward for all potential buyers. Members of the consortium also include TFI Asset Management Limited, and Great Wall Capital Co., Ltd. The consortium said, "The consortium urges the Special Committee to carefully evaluate the latest non-binding indicative all-cash offer of $26.50 per share from the consortium which is the highest among all of the offers submitted, effectively valuing the firm at approximately $1.64 billion, and to allow the consortium to conduct customary due diligence in order to move forward with its proposal. The sales process must be transparent and genuine for all potential bidders for it to be in the best interest of Hollysys shareholders and realize the true value of the Company. The consortium also calls on the directors of Hollysys to respect the rights of its shareholders and convene the legitimately requested special meeting immediately. As was recognized in Hollysys' statement on October 30, 2023, the directors of Hollysys have received valid requests for a special meeting from shareholders holding more than 30% of the Company as of the demand record date previously set by the board. Ascendent Capital Partners, which holds 13.7% of the shares, has also publicly called on the directors of Hollysys to convene the special meeting. This brings the total shareholders requiring the directors to convene the special meeting to 46%. The right to meet is an unqualified and unfettered absolute right of the shareholders. The directors should convene the special meeting immediately to uphold their fiduciary duties. The fact that the special meeting has not been convened by the directors is causing the consortium to have serious concerns over Hollysys' conduct of the sale process and the accountability of the directors to their shareholders. It is unprecedented for a board of directors to refuse to voluntarily and timely convene a meeting which nearly half of their shareholders legitimately want held."

09:48 EST Buyer consortium increases offer to acquire Hollysys to $26.50 per share - A Buyer consortium led by Recco Control Technology and Dazheng Group announces that the consortium has submitted an increased all-cash offer of $26.50 per share, or approximately $1.64B, to acquire all outstanding shares of Hollysys Automation Technologies in a letter sent to the board on November 8, 2023. Members of the consortium also include TFI Asset Management Limited, and Great Wall Capital Co., Ltd, who have entered into a memorandum of strategic cooperation with Recco Control Technology and Dazheng Group in connection with the proposed acquisition of Hollysys. The consortium has engaged in constructive negotiation with lenders and is at the final stage to secure a binding and definitive commitment in support of the offer. The new $26.50 per share offer from the consortium represents: A 42% premium to Hollysys' closing share price of US$18.66 on August 23, 2023 - the undisturbed price before the consortium resubmitted its previous bid to the Company on August 24; A 28.6% premium to Hollysys' closing share price of $20.60 on November 3, 2023 - the undisturbed price before Ascendent Capital announced its takeover offer on November 6; and An increase in price of 6% from the consortium's previous offer of $25 per share, which was presented to the Board on August 24, 2023. The consortium is aware that on November 6, Ascendent Capital Partners - who owns 13.7% of the Company - expressed its support for the special meeting first requested by over 32% of the Company's shareholders to the Board on August 24, 2023. Ascendent has publicly requested that the Board hold the special meeting by December 1, 2023. Shareholders holding 46% of the shares are now demanding that the Board convene the requested special meeting. The consortium said, "This action by Hollysys' largest shareholder appears to be echoing our earlier advocacy and is reflective of shareholders' desire, and fundamental right, to have an independent Board in place that was elected by the shareholders themselves. It also invites the obvious question whether the existing Board has any legitimacy in representing its shareholders after refusing to voluntarily convene the special meeting its own shareholders have requested. The consortium urges the Company's board of directors to listen to the voice of nearly half its shareholders. The Board must respect the rights of its shareholders and convene the legitimately requested special meeting without further delay. A transparent and thorough sale process should be led by independent directors who represent, and are elected by, Hollysys shareholders. This is the best way to ensure value is maximized for all shareholders."

09:47 EST BP Prudhoe Bay falls -6.7% - BP Prudhoe Bay is down -6.7%, or -23c to $3.29.

09:47 EST Altus Power falls -7.8% - Altus Power is down -7.8%, or -41c to $4.85.

09:47 EST Tetra Technologies rises 12.2% - Tetra Technologies is up 12.2%, or 53c to $4.83.

09:45 EST Royalty Management Holding Corp trading halted, volatility trading pause

09:39 EST Micromobility.com's Helbiz announces expansion into U.S. market - Helbiz announced its strategic expansion into the U.S. market, starting with a profit-driven micro-mobility service in Tampa. Helbiz is one of only two scooter operators granted the opportunity to redefine urban transport in Tampa, FL, with a permitted fleet of 1,500 scooters.

09:35 EST Westrock Coffee trading resumes

09:31 EST I3 Energy announces capital reduction - i3 Energy announces that the court order cancelling i3 Energy's share premium account and the associated court approved statement of capital, has been delivered to the Registrar of Companies, and the Capital Reduction will become effective upon the registration of the court order by the Registrar of Companies, which is expected to occur in the next few days.

09:24 EST Mullen Automotive announces new EV battery facility in California - Mullen Automotive announced a new high-energy facility in Fullerton, California, expanding the company's overall U.S. footprint, including EV battery development and production capabilities. This new Southern California facility is dedicated to producing American-made EV battery packs. Mullen's high-energy pilot facility in Monrovia, California, will be consolidated with the recently purchased Romeo Power assets at the company's new high-energy and high-volume battery pack production facility in Fullerton, California. Mullen plans to close the Monrovia facility by the end of 2023, transferring existing battery testing and production equipment to the brand new and state-of-the-art location in Fullerton. Beginning in December 2023, Mullen will begin calibration of the solid-state polymer battery BMS for integration into the Class 1 EV cargo van. The company will begin drivable testing of the solid-state polymer battery packs in the Class 1 EV cargo van in Q1 2024.

09:22 EST Blue Star Foods signs 2-year bid award purchase agreement with Sysco - Blue Star Foods (BSFC) announced a recently signed a 2-year bid award purchase agreement with Sysco (SYY). The Bid Award Purchase Agreement is effective starting immediately, and is for purchase of Blue Star's awardbrands such as Blue Star, Pacifika and Good Stuff.

09:20 EST Nvidia to supercharge Hopper AI computing platform - Nvidia has supercharged the world's leading AI computing platform with the introduction of the NVIDIA HGX H200. Based on Nvidia Hopper architecture, the platform features the Nvidia H200 Tensor Core GPU with advanced memory to handle massive amounts of data for generative AI and high performance computing workloads. H200-powered systems from server manufacturers and cloud service providers are expected to begin shipping in Q2 2024. Amazon Web Services, Google Cloud, Microsoft Azure and Oracle Cloud Infrastructure will be among the first cloud service providers to deploy H200-based instances starting next year, in addition to CoreWeave, Lambda and Vultr.

09:18 EST Kayne Anderson Energy, Kayne Anderson Midstream/Energy Fund complete merger - Kayne Anderson Energy Infrastructure Fund announced the completion of the merger of Kayne Anderson NextGen Energy & Infrastructure. KYN's post-Merger total assets and NAV were approximately $2.3 billion and $1.7 billion, respectively. KYN's post-Merger NAV per share was $9.95, with approximately 169.1 million shares outstanding.

09:16 EST Zynex submits FDA application for next generation NMES device - Zynex announced that it has submitted a 510(k) application to the U.S. Food and Drug Administration, FDA, for the M-Wave Neuromuscular Electrical Stimulation, NMES, device. The M-Wave is set to replace its predecessor, the E-Wave, which has been fundamental in NMES treatments across the U.S. since 1998. The E-Wave has helped over 17,500 patients with muscle-related issues such as drop-foot, quad rehabilitation, shoulder subluxation, and hand rehabilitation. "We are excited to introduce the M-Wave, a device that showcases our ongoing commitment to improving the lives of patients dealing with neuromuscular conditions," said Thomas Sandgaard, CEO at Zynex Medical. "The M-Wave will be another game-changer, providing a more effective and user-friendly treatment option for patients and a valuable tool for healthcare professionals. I believe that this next-generation device will be able to build upon the need for customizable NMES treatments in clinical and home settings."

09:15 EST Supermicro expands AI solutions with support for NVIDIA HGX H200 - Supermicro is expanding its AI reach with the upcoming support for the new NVIDIA HGX H200 built with H200 Tensor Core GPUs. Supermicro's industry leading AI platforms, including 8U and 4U Universal GPU Systems, are drop-in ready for the HGX H200 8-GPU, 4-GPU, and with nearly 2x capacity and 1.4x higher bandwidth HBM3e memory compared to the NVIDIA H100 Tensor Core GPU. In addition, the broadest portfolio of Supermicro NVIDIA MGXTM systems supports the upcoming NVIDIA Grace Hopper Superchip with HBM3e memory. Supermicro's rack scale AI solutions accelerate the performance of computationally intensive generative AI, large language Model training, and HPC applications while meeting the evolving demands of growing model sizes.

09:14 EST Gannett and Home Solutions announce exclusive agreement - Gannett and USA TODAY announced a multi-year strategic partnership with Home Solutions, a leading digital media company that helps homeowners make informed decisions about services and projects in their homes. Through this partnership, Home Solutions will reach Gannett's extensive audience, making it easy for readers to both choose and connect with the right home services provider for their projects. "Partnering with Home Solutions to provide essential services for homeowners across the nation is exactly what our readers want and need," said Kate Gutman, Gannett Senior Vice President of Content Ventures. "Making it simple and accessible for residents to secure the trusted services they need whether they rent or own is what this partnership hopes to accomplish. We believe this new vertical will provide essential content and go a long way to improving the homes and lives of our dedicated readers."

09:13 EST Asure Software launches Treasury Compliance Services - Asure announced the launch of its Treasury Compliance Services specifically designed to assist regional and niche payroll providers with the stringent compliance demands related to money movement. This service strategically addresses the requirements of the money transmission laws in the various states, which have increased regulatory requirements for companies moving money associated with payroll transactions. The Treasury Compliance Services leverage Asure's existing commercial banking and payments processing services, provided by J.P. Morgan. The Treasury Compliance Services are set to be available in Q4, marking a significant step in supporting payroll companies to manage their compliance needs effectively and efficiently.

09:13 EST AMD announces AMD Radeon PRO W7700 - AMD announced the AMD Radeon PRO W7700, the most powerful professional workstation graphics card under $1,000, offering an ideal combination of reliability, stability and extraordinary price/performance for content creation, CAD and AI applications. The new workstation graphics card is designed to meet the evolving demands of professional workflows, including increasingly complex computer-generated designs, the continual growth in the development of visual effects and animations, a global surge in construction, and the explosive growth in advanced AI applications. The AMD Radeon PRO W7700 graphics card unleashes professionals' creativity through exceptional performance, stunning visuals and future-ready capabilities.

09:12 EST Charles River, Aitia in deal to use Logica in discovery for NDDs, oncology - Charles River Laboratories and Aitia, a leader in the application of Causal AI and Digital Twins, announced a strategic agreement that gives Aitia access to Logica, Charles River's Artificial Intelligence powered drug solution platform, for the optimized discovery and early development of multiple therapeutic programs for neurodegenerative disease and oncology.Under the terms of the agreement, Aitia will deploy Logica across their portfolio of novel drug targets with the aim of creating and advancing drug candidates for neurological indications, including Alzheimer's, Parkinson's, and Huntington's diseases and cancers, including prostate cancer and multiple myeloma. According to the World Health Organization , Alzheimer's disease the most common form of dementia, affects 33M people globally, while Parkinson's disease impacts 8.5M, and it is estimated that Huntington's disease affects approximatively 1 in 10,000 people worldwide. There are currently no known cures for these diseases, and the prevalence of all three diseases rises year-over-year. In the field of oncology, there are approximately 1.4M new cases of prostate cancer and 160,000 new cases of multiple myeloma reported globally each year. Each cancer presents unique challenges with acquired resistance to novel therapies and corresponding rates of overall survival.

09:12 EST 3M sells LEAP III brand to DAC Technologies - 3M announced that DAC Technologies, a global leader in optical lens manufacturing solutions, has entered into an agreement to acquire the LEAP III brand. The acquisition closed on Oct. 30, 2023. As part of the sale of the LEAP III brand, 3M and DAC Technologies have entered into an exclusive supply agreement for 3M to supply DAC Technologies with the base component material from which LEAP III pads are made. "DAC Technologies is a leader in the ophthalmic products space and is the right company to continue the legacy of the LEAP III brand," said Matt Berdahl, 3M optical products global business leader. "DAC Technologies' knowledge of and focus on the ophthalmic market and its customers will allow the LEAP III brand to thrive and reach its potential in the market."

09:11 EST Abbott announces late-breaking data on HeartMate 3 Heart Pump - Abbott announced new late-breaking data that show advanced heart failure patients living with its HeartMate 3 heart pump who didn't receive aspirin as part of their blood-thinning medication regimen experienced fewer complications from bleeding and were associated with reduced hospital visits compared to patients who took aspirin daily following their implant. The data from the ARIES trial is the first to potentially shift how physicians manage their patients living with a HeartMate 3 heart pump. The data were presented during a late-breaking presentation at the 2023 American Heart Association's Scientific Sessions in Philadelphia and simultaneously published in The Journal of the American Medical Association. The ARIES trial studied more than 600 patients and found that HeartMate 3 patients who didn't receive aspirin but continued using the standard post-implant vitamin-K antagonist treatment regimen met the primary endpoint by showing non-inferiority of no aspirin to aspirin. The HeartMate 3 patients who did not take aspirin spent 47% fewer days in the hospital due to a nearly 40% decrease in bleeding events compared to patients who continued to take aspirin daily. "The ARIES study moves the needle forward in improving the journey of advanced heart failure patients with a marked improvement in bleeding events, healthcare resource use and cost-savings by a simple decision to avoid the use of aspirin," said Mandeep Mehra, M.D., executive director of the Center for Advanced Heart Disease and the William Harvey Distinguished Chair at Brigham and Women's Hospital in Boston, Mass. "The data is so compelling that the magnitude of benefit observed in avoiding aspirin is similar to the impact of introducing a new device to the market."

09:10 EST LPL Financial announces Zambri Financial joins Linsco - LPL Financial announced today financial advisors Anthony S. Zambri and his son Anthony V. Zambri have joined LPL's employee advisor channel, Linsco by LPL Financial, to launch Zambri Financial. They reported having served approximately $180 million in advisory, brokerage and retirement plan assets and join LPL from Ameriprise. The Melville, N.Y., practice represents three generations of Zambris in financial services. They built the business organically over the years through referrals and financial educational events.

09:08 EST One Stop Systems unveils new Gen 5 AI transportable compute server - One Stop Systems to unveil its latest AI Transportable, a Gen 5 short-depth server at SC23, the international conference for high performance computing being held in Denver, Colorado on November 12-17, 2023. Gen 5 Short-Depth Server: OSS new Gen 5 AI Transportable compute server doubles the performance over previous generation for powering the most demanding intelligent edge applications. OSS new Gen 5 AI Transportable compute server doubles the performance over previous generation for powering the most demanding intelligent edge applications. Powered by four PCIe NVIDIA H100 Tensor Core GPUs, the OSS Gen 5 SDS addresses the growing demand for more powerful AI Transportables at the edge. By incorporating the highest-performing GPUs, networking and NVMe solid-state storage devices, it delivers double the bandwidth as compared to its Gen 4 predecessors.

09:06 EST Kairous announces contribution to trust account to extend deal period - Kairous Acquisition Corp. Limited announced that Kairous Asia Limited, the company's initial public offering sponsor, has deposited into the company's trust account an aggregate of $120,000, in order to extend the period of time the company has to complete a business combination for an additional one month period, from November 16, 2023 to December 16, 2023. The Company issued a promissory note to Sponsor with a principal amount equal to the amount deposited. The promissory note bears no interest and will be converted into the company's ordinary shares at a price of $10.10 per share at the closing of a business combination by the company. The purpose of the extension is to provide time for the company to complete a business combination.

09:05 EST HeartSciences' MyoVista wavECG selected by Cardiact - Heart Test Laboratories dba HeartSciences announced that its MyoVista wavECG has been selected by Cardiact Ltd to be used in its heart screening program of members of the Association of Garda Sergeants and Inspectors. In addition to the purchase of a MyoVista device, Cardiact has placed an initial supplies order covering 2,400 patient tests.

09:04 EST Astrotech subsidiary reports purchase order for seven of TRACER 1000 ETDs - Astrotech Corporation announced that its 1st Detect subsidiary has accepted "another significant purchase order" for seven of its TRACER 1000 explosives trace detectors, or ETDs, for an airport security checkpoint. The systems will be deployed in a European airport in Romania. "We're excited to begin Fiscal Year 2024 with increased sales and interest in the TRACER 1000 from the security checkpoint field. Based on the near-zero false alarm rate that mass spectrometry provides, we believe that the TRACER 1000 improves checkpoint efficiency and passenger throughput by reducing the need for time-consuming pat-downs," said Thomas Pickens III, Chairman and Chief Executive Officer of 1st Detect.

09:03 EST Aterian's Squatty Potty re-launches in Walmart stores nationwide - Squatty Potty announced that select Squatty Potty toilet stools have launched in Walmart (WMT) stores nationwide. Squatty Potty is a 100% owned brand of Aterian, Inc. (ATER). "Our partnership with Walmart represents a significant step forward in our previously announced omnichannel expansion of the Squatty Potty brand. Walmart's footprint offers unparalleled opportunities to educate consumers on the many benefits of using Squatty Potty," said Phil Lepper, Chief Revenue Officer of Aterian.

09:02 EST Format enters into marketing and distribution agreement with OTBC - Foremost Lithium Resource & Technology announced that it has entered into a marketing and distribution services agreement with an arm's length marketing firm, Outside The Box Capital Inc. of Oakville Ontario, to provide marketing services, including digital marketing services through various social media channels to broaden media distribution awareness about the company. The Marketing Agreement will have a term of six months starting on November 13, 2023, and Foremost will pay OTBC a cash fee of $100,000 plus applicable taxes and also grant to OTBC 36,000 stock options having an exercise price of C$3.65 per common share and an expiry date of one year from the date of grant. The stock options shall be subject to the terms and conditions of the company's current stock option plan.

09:01 EST Lixte Biotechnology provides update on clinical progress - Lixte Biotechnology provided an update on its progress, with Bas van der Baan, LIXTE's recently-appointed President and CEO, having said, "Since the beginning of this year, LIXTE has been expanding its collaborations with several prestigious, world-renowned cancer research institutions and pharmaceutical companies that are testing our LB-100 compound to improve chemotherapy and immunotherapy treatment outcomes. We believe that LB-100 may offer broad applicability to many types and stages of cancer, with the potential to benefit a wide range of patients."

08:59 EST Terns Pharmaceuticals announces late-breaking data from Phase 2a DUET trial - Terns Pharmaceuticals announced the late-breaking oral presentation of top-line data from its Phase 2a DUET clinical trial of TERN-501, an investigational orally administered thyroid hormone receptor-beta agonist for the treatment of NASH. TERN-501 was evaluated alone and in combination with the Company's liver-distributed farnesoid X receptor vagonist TERN-101. These data will be presented at The Liver Meeting, the annual meeting of the American Association for the Study of Liver Diseases, on Monday, November 13 at 2:00 p.m. ET in Boston, Massachusetts. TERN-501 monotherapy demonstrated significant reductions in liver fat content as early as Week 6. The study met its primary endpoint, with TERN-501 monotherapy demonstrating a mean relative reduction of 27% and 45% at 3 mg and 6 mg doses, respectively, versus a 4% reduction in the placebo group at Week 12; A significantly higher percentage of patients achieved a greater than or equal to30% MRI-PDFF reduction in TERN-501 arms and a greater than or equal to50% reduction with TERN-501 monotherapy at Week 12; TERN-501 monotherapy resulted in a significant and rapid decrease in cT1 with a significantly higher percentage of patients achieving a greater than or equal to80 ms reduction; TERN-501 combined with TERN-101 resulted in efficacy improvement or maintenance compared to TERN-501 monotherapy TERN-501 monotherapy arms demonstrated significant increases in SHBG and improved lipid levels, including significant reductions in apolipoprotein B and a decrease in low-density lipoprotein levels, when combined with TERN-101; TERN-501 was generally well tolerated, with treatment-related adverse events similar to the placebo group; Overall, there were low rates of gastrointestinal AEs reported similarly across all treatment arms; No treatment-related cardiovascular AEs or serious AEs were reported.

08:58 EST Tingo Group announces AFAN adopts Nwassa as exclusive marketplace platform - Tingo Group announced that its trade partner, the All Farmers Association of Nigeria, or "AFAN," has formally adopted Tingo Mobile's Nwassa as its exclusive marketplace platform for its members. "AFAN is the umbrella body of the 56 recognized commodities and agricultural associations in Nigeria, with branches in all 36 states of Nigeria. In 2022, as part of its strategy to make sustainable agriculture the core foundation of Nigeria's economy, AFAN announced a national program and commitment to register all farmers across Nigeria, with the potential to grow its membership to 60 million. Tingo Mobile is working closely with AFAN to support it in achieving its goal, and to grow its own customer base in Nigeria to 60 million. Supported by a wide-reaching national marketing campaign across Nigeria, AFAN is promoting the Nwassa marketplace platform to all its members, and to potential new members," the company said.

08:55 EST Conduent implements toll relief programs for low-income families - Conduent's Conduent Transportation is helping agencies implement programs to ease the financial burden of roadway tolls for motorists, benefiting low-income individuals and families. This summer, the Bay Area Toll Authority and its partners launched two programs with support from Conduent that are now available for drivers with overdue payments from toll violations in the San Francisco area. The first program offers all motorists, regardless of income level, a one-time full or partial violation penalty waiver through September 2024. Partner agencies Golden Gate Bridge and express lane operators also are offering full or partial waivers, which BATA administers. The second program, which offers a payment plan designed to make paying off tolls, fees and penalties easier, is open to any low-income motorists who have received toll violations on Bay Area bridges and express lanes. Those who qualify can have all of their violation penalties waived and can pay off any remaining balance of $100 or more with a payment plan. Conduent Transportation is a provider of automated and analytics-based smart mobility solutions for government agencies.

08:53 EST Sellas Life Sciences receives favorable FDA feedback on BLA for galinpepimut-S - Sellas Life Sciences concluded a Type C meeting with the FDA regarding the company's Chemistry, Manufacturing, and Controls sections in a potential biologics license application - BLA - for Sellas' lead product candidate, galinpepimut-S, or GPS. Sellas submitted a CMC Briefing Package to the FDA which provided an up-to-date overview of the extensive work completed for the GPS CMC program and commercial manufacturing and regulatory plans. The FDA reviewed this package of data and accompanying questions to the agency and responded with favorable guidance. To date, the company has successfully completed numerous clinical development and CMC objectives in advancing GPS monotherapy into its Phase 3 REGAL study in patients with acute myeloid leukemia in the maintenance setting after achievement of second complete remission.

08:52 EST Xcel Brands announces license with ALPHA OES for Longaberger - Xcel Brands announced a new licensing agreement with ALPHA OES, a provider of eCommerce services and strategies for brands. Under the terms of the licensing agreement, ALPHA OES will take over the day-to-day operations for Xcel's Longaberger eCommerce business. "We're excited to partner with ALPHA OES on the Longaberger brand. Since we acquired Longaberger in 2019, we've been able to evolve the business from a direct sales company into a social commerce marketplace for home products featuring Longaberger's American made baskets. We believe that partnering with ALPHA OES, who is an expert in investing in and driving profitable growth eCommerce businesses that show strong brand affinity will help us continue to grow the Longaberger brand and business," said Robert D'Loren, Chairman and CEO of Xcel Brands.

08:49 EST Aligos Therapeutics presents clinical, nonclinical data at AASLD meeting - Aligos Therapeutics announced that clinical and nonclinical data for its thyroid hormone receptor-beta drug, ALG-055009, were presented Saturday, November 11th at The Liver Meeting of the American Association for the Study of Liver Diseases, being held in Boston, Massachusetts, November 10 - 14, 2023. The clinical and nonclinical posters for these data can also be found on the "Scientific Presentations & Conferences" section of the Aligos website. The clinical poster describes a Phase 1 study which evaluated 14 oral daily doses of up to 1.0 mg ALG-055009 solution formulation in hypercholesterolemic subjects. Important highlights include: ALG-055009 was well tolerated with no safety signals identified; No clinical evidence of hyper- or hypo-thyroidism was observed; As expected for a thyromimetic, ALG-055009 dose responsively; Increased sex hormone binding globulin levels; Lowered lipids levels; ALG-055009 exposures increased in a dose proportional manner with low variability and a ~20 hour half-life that supports QD dosing; The planned Phase 2a gelcap formulation delivered exposures ~86% of the solution formulation and did not demonstrate a food effect; The nonclinical poster describes in vitro and in vivo studies which characterize the properties of ALG-055009. Important highlights include: ALG-055009 is 5-47 times more potent than resmetirom and VK-2809; ALG-055009 is more beta selective than resmetirom and VK-2809 in cell based assays Lipid levels decreased in a dose responsive manner in in vivo models; In 13-week repeat dose toxicology studies, ALG-055009 was well tolerated with safety margins supporting dosing in the planned Phase 2a clinical study .

08:47 EST BioVie announces 'positive' clinical safety data from study of BIV201 - BioVie announced "positive" clinical safety data from the company's Phase 2b open-label study evaluating the efficacy and safety of BIV201, terlipressin administered as a continuous infusion, with standard of care in patients with refractory ascites due to cirrhosis. The data will be highlighted today in a late-breaking poster presentation titled "Safety and Tolerability of Continuous Infusion Terlipressin In Patients with Decompensated Cirrhosis and Refractory Ascites: A Phase 2, Randomized, Controlled, Open-Label Study" at The American Association for the Study of Liver Diseases - AASLD - The Liver Meeting 2023 in Boston, MA. "Our Phase 2b results mark a significant step toward providing a treatment for cirrhosis patients with refractory ascites, of whom face a survival rate as low as 50% within a year of diagnosis.1 Currently, the only options for these patients are transjugular intrahepatic portosystemic shunt surgery or liver transplantation, which are invasive and come with numerous potential life-altering complications," said Cuong Do, BioVie's President and Chief Executive Officer. "These data being presented, coupled with statistically significant efficacy, allowed BioVie to halt the trial prior to completion and further strengthen our confidence in accelerating BIV201's development into Phase 3 trials, which we expect to initiate in Q2 2024."

08:46 EST IntelGenx reminds shareholders to vote at upcoming special meeting - IntelGenx Technologies wishes to remind its shareholders of record as of October 2, 2023 of the importance of a vote FOR the various proposals detailed below at the upcoming special meeting of Shareholders to be held on November 28, 2023 as a virtual meeting only. At the Special Meeting, Shareholders will be asked to vote: to amend the certificate of incorporation of the Company to increase the authorized common stock from 450,000,000 shares of common stock to 580,000,000 Shares; to approve for purposes of complying with Sections 607(e) and 607(i) of the Toronto Stock Exchange Company Manual, the issuance of Shares at prices which may be less than the minimum price permitted under the rules of the TSX in connection with certain financing transactions involving atai Life Sciences AG previously disclosed by the Company on August 31, 2023, as further described in the proxy statement of the Company dated October 16, 2023; to approve for purposes of complying with Section 607(g)(i) of the TSX Company Manual the issuance of Shares in excess of 24.99% of the issued and outstanding Shares in connection with the Financing Transactions, as further described in the Proxy Statement; to approve for purposes of complying with Section 607(g)(ii) of the TSX Company Manual, the issuance of Shares to "insiders" of the Company in excess of 9.99% of the issued and outstanding Shares in connection with the Financing Transactions, as further described in the Proxy Statement; and to approve the adjournment of the Special Meeting, if necessary, to continue to solicit votes in favor of the foregoing proposals.

08:44 EST OSI Systems gets multiple orders for approximately $4M for missile component - OSI Systems announced that its Optoelectronics and Manufacturing division has received multiple orders for approximately $4M in aggregate to provide missile guidance and detection components to a leading defense electronics original equipment manufacturer.

08:42 EST Inogen appoints Kevin Smith as CEO - Inogen announced that its board of directors has appointed Kevin Smith as Inogen's president and CEO and a member of the board of directors, effective immediately, succeeding Nabil Shabshab. Smith brings more than 20 years of commercial leadership experience in the medical device industry, including respiratory care and durable medical equipment businesses. He most recently served as CEO at Sirtex Medical.

08:40 EST Dare Bioscience to present Phase 2b results of Sildenafil Cream in FSAD - Dare Bioscience and its collaborator Strategic Science & Technologies, a Cambridge, MA based novel topical drug delivery company, announced that preliminary efficacy findings from the exploratory Phase 2b RESPOND clinical study of Sildenafil Cream, 3.6% in women with female sexual arousal disorder - FSAD - will be presented at the upcoming Sexual Medicine Society of North America 24th Annual Meeting. Andrew Goldstein, Medical Advisor for Dare Bioscience, said, "The results I will discuss highlight important attributes and meaningful improvements across the women who benefitted from Sildenafil Cream treatment most significantly in this study, which included women with not only female sexual arousal disorder but also those who suffered from a lack of sexual desire along with decreased arousal." "The findings from this study in arousal, desire, and orgasm among the women treated with Sildenafil Cream support the potential of Sildenafil Cream to provide improvements across the sexual experience continuum, as has been seen among men treated for erectile dysfunction with sildenafil products," said James Simon, Clinical Professor, Obstetrics and Gynecology, George Washington University. Sildenafil is the active ingredient in a tablet for oral administration currently marketed under the brand name Viagra for the treatment of ED in men. Sildenafil Cream is an investigational, proprietary topical cream formulation designed to be used on-demand at the time of sexual activity to increase blood flow to the genital tissue in women. If development is successful, Sildenafil Cream has the potential to be the first product approved by the FDA to treat any form of arousal disorder in women.

08:38 EST Daxor presents data from Phase 1 NIH sponsored RCT on BVA-100 - Daxor Corporation announces the presentation of data from a Phase I National Institute of Health sponsored randomized control trial from two Veterans Affairs Medical Centers, validating treatment decisions guided by the Company's BVA-100 diagnostic blood test benefitted patients with acute decompensated heart failure. Data were presented at the American Heart Association Scientific Sessions 2023 at the Pennsylvania Convention Center in Philadelphia, PA on November 11, 2023. Key findings included: This successful pilot study paves the way for further funding opportunities tied to a Phase II project now that both the need for blood volume analysis and the practicality of applying its results has been demonstrated; Data showed that on average 7 out of 10 ADHF patients are not being accurately diagnosed. BVA was more accurate than clinical assessment which was correct only 53% for volume and 56% for anemia; A BVA-guided treatment protocol was successfully incorporated into the clinical workflow for ADHF; Volume-appropriate treatment was significantly more likely in patients who received BVA-guided care showing that the results of BVA can be applied by clinicians in real-time in the clinical setting; The study titled, "Clinical Assessment of Volume Status in Heart Failure is Inaccurate at Detecting Hypervolemia and Anemia as Quantified by Blood Volume Measurement," prospectively compared the standard of care treatment decisions to those in a BVA-guided fluid management protocol. Clinical assessments of volume status and anemia were collected for all patients prior to BVA measurement at hospital admission and post-discharge. The results showed that the accuracy of volume status and anemia as determined by clinical assessment was only 53% and 56%, respectively, compared to BVA indicating that approximately 7 out of every 10 patients did not receive an accurate diagnosis of their volume condition. Patients in the BVA-guided arm received treatment informed by the BVA test results, in the blinded arm volume was only assessed using clinical tools and biomarkers absent the BVA results.

08:36 EST Tenax Therapeutics' IND application for TNX-103 cleared by FDA - Tenax Therapeutics announced that the FDA has reviewed and cleared the company's Investigational New Drug - IND - Application for TNX-103 oral levosimendan for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction - PH-HFpEF -, enabling Tenax to proceed with the first of two Phase 3 studies. The LEVEL Study is expected to launch in Q4 2023.

08:34 EST Nuvei integrates BLIK into its APM suite for eCommerce - Nuvei Corporation announces that it has added direct connectivity to BLIK, the leading mobile payment method in Poland, into its suite of 669 APMs available for eCommerce businesses to offer through a single integration. BLIK enables users to make instant payments directly through their mobile banking app. In addition to traditional BLIK payments, Nuvei also enables merchants to offer BLIK One Click. Nuvei Chair & CEO commented: "It is critical for eCommerce businesses to offer their customers a choice of all the payment methods they prefer, and BLIK is rapidly becoming one of the most relevant payment methods in Poland. Adding BLIK to our suite of over 600 APMs through a single integration enables our partners to efficiently reach their customers more completely."

08:32 EST Re/Max Holdings names Carlson as CEO, board member - RE/MAX Holdings (RMAX) announced that following a comprehensive search, the Company's Board of Directors has appointed Erik Carlson as Chief Executive Officer and a member of the RE/MAX Holdings Board of Directors, effective today. Carlson was most recently President and CEO of DISH Network (DISH), a Fortune 200 connectivity company, where he ran DISH's two largest businesses, DISH TV and SLING TV.

08:29 EST Spectaire Holdings, Sankofa sells $750,000 of carbon offset credits - Spectaire Holdings announced the sale of 12,500 carbon offset credits for $750,000 with Sankofa acting as broker to the transaction. This transaction marks a significant milestone in the carbon offset marketplace, as management believes these credits will be some of the first credits sold based on measurement of actual emissions in the field.

08:28 EST Intercept's OCA-bezafibrate combination achieves remission in PBC - Intercept Pharmaceuticals announced new data from two Phase 2 studies, including a topline full data analysis and an interim analysis, evaluating the effects of the investigational combination of farnesoid X receptor agonist, obeticholic acid and peroxisome proliferator-activated receptor agonist, bezafibrate, on multiple key serum biomarkers in primary biliary cholangitis - PBC - that have been shown to predict clinical outcomes. The primary endpoint of both studies is change in alkaline phosphatase from baseline to Week 12. OCA5-10/B400 SR showed a -60.6% change in ALP from baseline at week 12 - primary endpoint -. At week 12, OCA5-10/B400 SR induced biochemical remission in 44.4% of patients vs. 31.6% in B400 SR, 31.6% in OCA5-10/B200 IR and 15.8% in B200 IR. 66.7% of patients in the OCA5-10/B400 SR arm achieved normalization of ALP and 100% achieved TB less than or equal to0.6xULN at week 12. OCA5/B400 IR showed a -65.4% change in ALP from baseline at week 12 - primary endpoint -. At week 12, OCA5/B400 IR induced biochemical remission in 40.0% of patients compared to 18.2% in B400 IR, 11.1% in OCA5/B100 IR and 9.1% in B100 IR. 70.0% of patients in the OCA5/B400 IR arm achieved normalization of ALP and 90.0% achieved TB less than or equal to0.6xULN at week 12. The frequency of treatment-emergent adverse events was generally balanced across all arms in both studies. The company is continuing its two ongoing Phase 2 studies exploring a range of therapeutic doses and formulations for the combination of OCA and bezafibrate. The company expects to have the necessary data from the OCA-bezafibrate combination program to submit a request in 2023 for an End-of-Phase 2 meeting with the FDA.

08:27 EST Moleculin Biotech announces interim data in annamycin trials - Moleculin Biotech provided a preliminary update on recent clinical activity and expected near term milestones across its clinical development pipeline in its quarterly filing with the Securities and Exchange Commission. "Having 38% of subjects with a median age of 68 in our MB-106 AML study receiving a full course of Annamycin show a complete response with durability of up to approximately 8 months and counting, we believe, is exceptional while also demonstrating no cardiotoxicity," Dr. Paul Waymack, Senior Chief Medical Officer said. "Adding to this, we are showing in our Phase 1B/2 study with Annamycin treating soft tissue sarcoma with pulmonary metastases for subjects with no limit on prior therapies PFS of 2.2 months or better for 59% of the subjects. In subjects with fewer prior therapies and dosed with Annamycin at or below 330 mg/m2, this increased to 78% and, additionally, we are showing PFS of 3.4 months for 56% of these subjects. Having a preliminary median of 11.3 months of overall survival once the subject has entered into our Phase 1B study, is exciting as these subjects were heavily pre-treated. For the overall study, we have an opportunity for the Extended OS and PFS data to get better as subjects continue to be monitored."

08:26 EST IO Biotech appoints Helen Collins to board of directors - IO Biotech announced the appointment of Helen Collins, MD, to its board of directors. Dr. Collins is an industry veteran with significant experience in oncology/hematology drug development and will serve on the Research and Development Committee of the Board. Dr. Collins joins the IO Biotech board of directors with more than 25 years of medical experience. She is currently the Chief Medical Officer at Enliven Therapeutics.

08:25 EST BIO-key showcases authentication innovations Boston Cyber Security Summit - BIO-key International announced the company will sponsor the seventh annual Boston Cyber Security Summit. The one-day event will be held at the Westin Copley Place on November 14th. BIO-key will showcase its differentiating capability on center stage to high-level decision makers, including: FIDO2-compliant passwordless authentication options that include phoneless and tokenless MFA, in addition to offering all of the traditional multi-factor authentication approaches commonly used in mainstream MFA solutions. Unlike any other product or solution in the authentication category, BIO-key's IBB allows users to take advantage of a true biometric passwordless authentication solution that does not require the use of phones or tokens to assist in the authentication process. With phish-resistant MFA and passwordless authentication top of mind for organizations of all sizes and across all industries, conference attendees will learn how the company's award-winning unified IAM platform, PortalGuard(R), along with Identity-Bound Biometrics, helps fill a critical business use case that traditional MFA overlooks - users who cannot use a phone or token to authenticate.

08:23 EST Forward Air files answer, counterclaim against Omni Newco - Forward Air announced that it has filed under seal an answer and counterclaim against Omni Newco in the Delaware Court of Chancery relating to the transactions contemplated by the merger agreement, dated August 10, entered into by Forward, Omni and certain other parties. As previously disclosed by Forward, on October 31, Omni filed a complaint against Forward in the Delaware Court of Chancery alleging, among other things, that Forward is in breach of its obligation to close the transactions contemplated by the merger agreement and seeking specific performance to compel Forward to close and related declaratory relief. On Friday, November 10, Forward filed its response to the complaint and a counterclaim for declaratory relief. Forward intends to file a public version of its answer and counterclaim by November 17. Forward believes that Omni has not complied with certain of its obligations under Sections 7.03 and 7.14 of the merger agreement. Because of Omni's continuous delays and repeated misrepresentations, Forward no longer believes Omni to be acting in good faith with respect to the merger agreement. Consequently, Forward believes the closing condition contained in Section 8.02 of the merger agreement will not be satisfied at the anticipated closing of the transactions under the merger agreement. Forward is seeking an order from the Delaware Court of Chancery declaring that it is not obligated to close the transaction and that it is entitled to terminate the merger agreement.

08:22 EST Aethlon Medical appoints Frakes as interim CEO, Cipriani as COO - Aethlon Medical announced that James Frakes, M.B.A., Chief Financial Officer of the Company, was appointed as Interim Chief Executive Officer, CEO, replacing Charles Fisher, Jr. M.D. Frakes also was appointed as a member of the Board of Directors and will remain as Chief Financial Officer of the Company. Additionally, Guy Cipriani, formerly Chief Business Officer, has been appointed as the Company's Chief Operating Officer, COO, and has resigned from the Board of Directors. Each of the appointments and the resignation took effect on November 7, 2023.

08:19 EST CymaBay announces results from RESPONSE Phase 3 study of seladelpar - CymaBay Therapeutics announced that the results from its RESPONSE Phase 3 registration study evaluating seladelpar, a potent, selective, orally-active delpar, or PPAR agonist, in adult patients with primary biliary cholangitis will be featured as an oral presentation in today's Late Breaker Session of the American Association for the Study of Liver Diseases', AASLD, The Liver Meeting 2023 in Boston, Massachusetts. RESPONSE was a double-blind, placebo-controlled, global study of one-year duration that randomized 193 PBC patients in a 2:1 ratio to seladelpar 10 mg or placebo, once daily. The primary endpoint was a composite of ALP and total bilirubin previously accepted by the U.S. Food and Drug Administration and European Medicines Agency for registration studies in PBC. The composite endpoint was achieved in 61.7% of patients on seladelpar vs. 20.0% on placebo. The key secondary endpoint of ALP normalization occurred in 25% of patients receiving seladelpar vs. 0% for patients on placebo. The average decrease in ALP for patients on seladelpar was -133.9 U/L vs. -16.9 U/L for patients on placebo. Compared to placebo, seladelpar reduced alanine aminotransferase at Month 12 by 23.5% vs. 6.5% and gamma-glutamyl transferase by 39.1% vs. 11.4%. The study also measured change in patient-reported pruritus, as a key secondary endpoint using the daily numerical rating scale. The pruritus endpoint was met at Month 6 among patients with baseline NRS greater than 4 reporting decreases of 3.2 points with seladelpar vs. 1.7 for patients on placebo. Notably, these improvements were sustained through Month 12. Approximately 37.3% of patients enrolled had moderate-to-severe pruritus based on an NRS score greater than or equal to 4 at baseline. A statistically significant reduction in pruritus was also observed at Month 6 and at Month 12 for patients in the intent-to-treat population, which includes all patients irrespective of their NRS score at baseline.

08:17 EST Royalty Pharma to fund up to $125M for LAI Program in collaboration with Teva - Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries(TEVA) and Royalty Pharma (RPRX), announce a collaboration to further accelerate the clinical research program for Teva's olanzapine LAI TEV-'749 by entering into a funding agreement of up to $125M to offset program costs. Olanzapine LAI TEV-'749 is a once-monthly subcutaneous long-acting injection of the atypical antipsychotic olanzapine that is currently in Phase 3 for the treatment of schizophrenia and has the potential to be the first long-acting olanzapine with a favorable safety profile. "Since launching Teva's Pivot to Growth strategy in May 2023, we have been working on novel and expedited ways to both continue to invest in our robust innovative pipeline while supporting the growth of our in-line businesses," said Richard Francis, President and CEO of Teva. "We are excited to collaborate with Royalty Pharma, a leading funder of innovation with a strong track record, experience, and reputation. This funding agreement enables us to continue to accelerate the development of olanzapine LAI TEV-'749 , a critical program for us, without impacting resources dedicated to our innovative and generic medicines." Under the agreement, Royalty Pharma will provide Teva up to $100M option to increase the total funding amount to $125M. Upon U.S. Food and Drug Administration approval, Teva will pay Royalty Pharma the total amount funded over five years, as well as low to mid-single digit royalties upon commercialization. If Teva chooses not to file a New Drug Application with the FDA following positive Phase 3 study results, then Teva will pay an amount equal to 125% of the total amount funded. Teva will lead the development and commercialization of olanzapine LAI TEV-'749 globally.

08:16 EST Mach Natural Resources adds accretive acquisition in Anadarko Basin - Mach Natural Resources signed an agreement with Paloma Partners IV, LLC, a privately-held Delaware limited liability company backed by EnCap Investments and its affiliated companies, to acquire certain interests in oil and gas properties, rights and related assets located in certain counties in Oklahoma for a total cash consideration of $815 million, subject to customary terms, conditions, and closing price adjustments. The Acquisition is expected to close December 29, 2023, with an effective date of September 1, 2023.

08:15 EST Alzamend Neuro submits AL001-PTSD01 IND application to FDA - Alzamend Neuro announced that it has submitted an investigational new drug, or IND, application to the FDA for the initiation of study AL001-PTSD01, a Phase IIA plasma/brain pharmacokinetics clinical study of AL001 for treatment of patients with PTSD. After receipt of a "study may proceed" communication from FDA, Alzamend plans to initiate a Phase IIA study to characterize AL001 improvements of lithium levels in the brain compared to a marketed lithium salt in PTSD patients. Alzamend anticipates that the new drug application, or NDA, development program for PTSD may, for safety, qualify for a 505 NDA pathway to FDA approval, which can be available to new formulations of an approved drug.

08:13 EST Tecsys appoints Kirkwood to board of directors - Tecsys announces the appointment of UK-based Andrew Kirkwood to its Board of Directors, effective October 12, 2023. Kirkwood brings a wealth of experience to Tecsys, with more than two decades of global leadership at high-growth supply chain organizations. In conjunction with Kirkwood's appointment, the Board will realign its Board committees. Drawing from his background in building global markets for supply chain technology firms, Kirkwood has a proven track record of driving both organic and inorganic growth. Notably, Kirkwood served as CEO at BluJay Solutions until its successful exit to E2Open in 2021.

08:12 EST SunCar Technology announces strategic cooperation with Heilongjiang Branch - SunCar Technology announces its recent strategic agreement with the Heilongjiang branch of Agricultural Bank of China. This one-year agreement marks a significant milestone in SunCar's expansion strategy within the financial services sector. Key Collaboration Highlights: Under this agreement, SunCar is set to enhance the banking experience by offering a comprehensive package of services, including but not limited to car washes, designated driver provisions, and streamlined airport transfer solutions. Services will be integrated across various bank departments, including the Credit Card and Personal Banking departments. The current exclusivity with the Heilongjiang branch presents a scalable model for potential future expansion across the Agricultural Bank of China's network, leveraging SunCar's solidified presence and proven success in the automotive service market.

08:10 EST Realty Income, Digital Realty form build-to-suit data center joint venture - Digital Realty (DLR) and Realty Income Corporation (O) announced that they have established a joint venture to support the development of two build-to-suit data centers in Northern Virginia. Realty Income invested approximately $200 million to acquire an 80% equity interest in the venture, while Digital Realty maintains a 20% interest. Each partner will fund its pro rata share of the remaining $150 million estimated development cost for the first phase of the project, which is slated for completion in mid-2024. The build-to-suit facilities were 100% pre-leased to an S&P 100 investment grade client prior to construction and are expected to generate a 6.9% initial cash lease yield upon lease commencement in mid-2024. "We are delighted to partner with Realty Income, a blue-chip net-lease REIT, in their first investment in the data center sector," said Digital Realty President and Chief Executive Officer Andy Power. "The formation of this development joint venture supports our customer's build-to-suit requirements with a like-minded, long-term investor as our partner. The transaction also further bolsters and diversifies Digital Realty's capital sources, while enhancing our flexibility so that we can prudently support our stakeholders' longer term capacity requirements."

08:08 EST Spire board increases quarterly dividend from 72c to 75.5c per share - The board of directors of Spire unanimously agreed to increase the quarterly common stock dividend to $0.755 per share from $0.72 per share. This full year $0.14 per share increase brings the annualized rate to $3.02, an increase of 4.9%. "Spire's growing dividend reflects the Company's performance, strong financial position and the board's confidence in our long-term growth strategy going forward. It is also a key part of how we deliver value to our shareholders while positioning Spire as a compelling investment," said Ed Glotzbach, chairman of the board of Spire.

08:03 EST Galectin Therapeutics expects cash to fund operations through December 2024 - As of September 30, 2023, the Company had $20.4 million of cash and cash equivalents. Additionally, the Company has $30 million remaining available under a $60 million line of credit provided by its chairman to fund operations. The Company believes it has sufficient cash to fund currently planned operations and research and development activities through at least December 31, 2024. The Company expects that it will require more cash to fund operations after December 31, 2024, and believes it will be able to obtain additional financing as needed. However, there can be no assurance that we will be successful in obtaining such new financing or, if available, that such financing will be on terms favorable to us.

08:00 EST LQR House, Cabal Tequila partner for marketing, awareness campaign - LQR House announces its partnership with Cabal Tequila, selecting LQR House to spearhead a bespoke marketing campaign. This initiative aims to generate viral content, elevating awareness and driving sales for Cabal Tequila. Capitalizing on LQR House's partnership with Alpha Liquor Distributors LLC, renowned for its expertise with major retailers including Costco and Total Wine, the strategic effort focuses on securing Cabal Tequila's placement on the shelves of these outlets, ensuring widespread visibility and a robust market presence.

07:59 EST Optex Systems announces $1.3M order for laser filter units - Optex Systems has been awarded a new contract from a U.S. Government Prime Contractor, in support of a visible sighting system. The order value is $1.3M with deliveries covering April 2024 through August 2024. With this order, the current Optex backlog is in excess of $42.5M.

07:55 EST Medigus subsidiary to develop Bubbl writing tool - Medigus 19.99% owned subsidiary Metagramm Software is developing Bubbl, a writing tool utilizing Machine Learning, Natural Language Processing, AI and Deep Learning technologies. According to Verified Market Research, the Global Writing Enhancement Software market will reach $887.9M by 2030 with a 11% CAGR from 2023-2030. Bubbl allows users to operate in different modes, including an interactive re-write floating window mode, interactive inline mode and grammar-only mode. Bubbl is designed to cater to a variety of writing needs with different profiles and features, including Business, Medical, Academic and Blogging.

07:53 EST R1 RCM to restate previously issued financial statements - R1 RCM announced its decision to restate its previously issued financial statements for the years ended December 31, 2022 and 2021 and interim periods, as well as for the first two quarters of 2023. Immediately prior to the scheduled filing of its Form 10-Q for the third quarter 2023, R1 identified errors related to the accounting for certain acquiree compensation costs incurred as a result of historical acquisitions. These expenses should have been recorded as "Other expenses" within the consolidated statements of operations and comprehensive income and instead were included in the purchase price allocations and ultimately recorded as goodwill in the consolidated balance sheets. R1 has determined that the drivers of the corrections are acquiree compensation expenses equal to approximately $7.8 million for 2022 and $8.4 million for 2021. As part of the restatement process, other less significant previously identified immaterial adjustments that were not recorded in the proper period will also be adjusted. Based on information currently available, R1 does not expect a material impact to 2022 and 2021 revenue or Adjusted EBITDA. The accounting errors are not expected to have a material impact on R1's previously reported results of operations for the first three quarters of 2023, or on its 2023 outlook. R1 continues to expect to achieve its 2023 targets, including delivering revenue of $2,255 million to $2,275 million, GAAP operating income of $130 million to $140 million and Adjusted EBITDA of $600 million to $615 million. In addition, this matter has no impact on R1's cash or business operations. It is important to note that the accounting errors did not result from any override of controls or misconduct, nor has the Audit Committee been informed of any issues related to an override of controls or misconduct. "This technical accounting issue was proactively identified by R1's internal team, at which time we immediately took action to identify any potential impact on past financial statements in conjunction with our auditors, Ernst & Young," said Lee Rivas, chief executive officer of R1. "At this time there is no expected material impact on our 2023 results of operations or outlook. As we look ahead, we remain confident in our ability to deliver on our 2023 outlook and drive long-term value through our excellent provider relationships, commitment to innovation and continued customer growth."

07:52 EST Sio Silica to go public through Pyrophyte Acquisition Corp. business combination - Sio Silica and Pyrophyte Acquisition Corp. (PYHT), a special purpose acquisition company, announced that they have entered into a definitive agreement for a business combination. The terms of the business combination reflect an implied enterprise value of $708M and equity value of $758M for the combined company, an approximate 80% discount to the net present value described above and includes approximately $150M of gross capital including equity, debt, royalties and Sio's cash on hand and additional $10M expected flow-through equity from a variety of institutional and individual accredited investors. Following the closing of the business combination, such proceeds are expected to be used to fully fund the construction of the first phase of Sio's extraction and processing facility in Winnipeg, Manitoba. Upon Closing, the name of the combined company will be Sio Silica Incorporated, and its common shares and warrants are expected to be listed on the New York Stock Exchange under the ticker (SIOS). Sio has approximately 15.2B tons of in situ high-purity silica including an estimated ~146M ton measured and indicated resource and an estimated 345M ton inferred resource and intends to initiate a mining plan that ensures a comprehensive and active environmental stewardship over the years to come. The terms of the Business Combination imply an enterprise value of $708 million and equity value of $758M for the combined company. Approximately $150M of gross capital, comprised of equity, debt, royalties and Sio's cash on hand, has been secured from a variety of institutional and individual accredited investors, including a credit facility provided by Riverstone Credit Partners, and other financing from Hite Hedge Asset Management and a large Canadian pension fund, and an additional $10M is expected to be secured from flow-through equity from a variety of individual accredited investors, to support the construction of the first phase of its extraction and processing facility. Availability under the credit facility with Riverstone Credit Partners is subject to certain conditions. In an effort to further strengthen its capital base and reduce debt levels, Sio and Pyrophyte may raise additional equity capital through incremental PIPE investments along with the potential contribution of up to approximately $97M of cash currently held in Pyrophyte's trust account, subject to redemptions by Pyrophyte shareholders that have not entered into non-redemption agreements. The business combination, which has been unanimously approved by the boards of directors of Sio and Pyrophyte, is subject to approval by Pyrophyte's and Sio's shareholders and other customary closing conditions. CEO Feisal Somji will continue to lead Sio, supported by a team of experienced operators. Pyrophyte's leadership team will actively introduce key relationships to help accelerate Sio's growth.

07:51 EST Vision Marine Technologies receives purchase order for propulsion system - Vision Marine Technologies has received an initial purchase order from Wired Pontoons for 25 units of the E-Motion 180E outboard and powertrain systems. This order marks the beginning of a transformative partnership, with Wired set to equip its pontoons with these 180 HP electric propulsion systems, responding to the growing marine consumer demand for electric marine propulsion. Over the past year, Wired has extensively tested the performance of its pontoons equipped with Vision Marine's systems. The positive feedback from boat show attendees and robust performance data have strengthened Wired's confidence in the E-Motion system as a game-changing solution in the recreational boating landscape, particularly for pontoon users.

07:49 EST VYNE Therapeutics expects cash to fund operations through 2025 - As of September 30, 2023, VYNE had cash and cash equivalents and restricted cash of $15.5 million. When adding the gross proceeds received from the PIPE, VYNE's cash and cash equivalents and restricted cash as of September 30, 2023 would have been approximately $103.7 million. VYNE currently anticipates that its cash and cash equivalents and restricted cash as of September 30, 2023, together with the gross proceeds from the PIPE, will be sufficient to fund its operations through the end of 2025.

07:46 EST Omega Therapeutics presents preclinical data on liver fibrosis and inflammation - Omega Therapeutics announced the presentation of new preclinical data from two different programs that demonstrated sustained upregulation of gene expression and coordinated pre-transcriptional downregulation of multiple genes in models of liver fibrosis and inflammation, respectively, at the American Association for the Study of Liver Diseases' The Liver Meeting 2023, taking place in Boston, November 10 - 14. Single administration of an EC in the humanized FRG mouse model resulted in induction of HNF4alpha mRNA levels compared to untreated FRG mice. EC-mediated induction of HNF4alpha expression in vivo in a mouse model of liver fibrosis led to decreased collagen deposition, a key marker of fibrosis. Treatment of mouse and human liver cells with ECs engineered to pre-transcriptionally downregulate the expression CXCL9, CXCL10 and CXCL11 resulted in robust mRNA downregulation and decreased protein levels of all three chemokines. Primary human hepatocytes stimulated with interferon gamma and treated with a single EC targeting CXCL9-11 resulted in a statistically significant decrease in mRNA expression and protein levels of each chemokine compared to INFG stimulation alone.

07:39 EST Camping World to acquire Youngblood RV in Springfield, Missouri, closes Q124 - Camping World Holdings announced that it is set to acquire Youngblood RV in Springfield, Missouri. The transaction is anticipated to close in the first quarter of 2024 and will increase the Company's Missouri location count to six. Marcus Lemonis, Chairman and CEO of Camping World commented, "The acquisition of Youngblood RV adds to our presence in the growing Springfield market with the addition of 16 service bays and lines from Grand Design and Forest River. We continue to be focused on our goal to increase our dealership count to over 320 locations over the next five years, through a combination of acquisitions, new store openings, and manufacturer exclusive locations."

07:35 EST Tyson Foods increases quarterly dividend to 49c per share - Effective November 10, 2023, the Board of Directors increased the quarterly dividend previously declared on August 10, 2023, to $0.49 per share on our Class A common stock and $0.441 per share on our Class B common stock. The increased quarterly dividend is payable on December 15, 2023, to shareholders of record at the close of business on December 1, 2023. The Board also declared on November 10, 2023 a quarterly dividend of $0.49 per share on our Class A common stock and $0.441 per share on our Class B common stock, payable on March 15, 2024, to shareholders of record at the close of business on March 1, 2024. We anticipate the remaining quarterly dividends in fiscal 2024 will be $0.49 and $0.441 per share of our Class A and Class B common stock, respectively. This results in an annual dividend rate in fiscal 2024 of $1.96 for Class A shares and $1.764 for Class B shares, or a 2% increase compared to the fiscal 2023 annual dividend rate.

07:34 EST DeFi Technologies announces Valour achieves major market share increase - DeFi Technologies announces that its subsidiary Valour has recorded significant achievements in market share and asset under management growth. In an additional development, Valour saw its Solana holdings overtaking Bitcoin as the leading asset. In October, Valour demonstrated remarkable performance on Swedish exchanges, with its digital asset market share nearing 28%, marking a substantial 10% increase from the previous month. Since the start of October, Valour has experienced a period of notable trade volume, including a substantial inflow of C$24.5 million, with C$7.5 million of this total arriving in the first five trading days of November. Additionally, since the start of November, Valour's AUM continued its surge, reaching C$320 million - up from C$259 million a 23% increase since October 30th with Solana emerging as the top asset, commanding close to C$115 million of the AUM. This indicates not only an exceptionally strong trend for the quarter but also robust demand for Valour's products in the Nordics.

07:34 EST PVH Corp. to divest Warners, Olga and True & Co. businesses for $160M - PVH Corp. announced that Basic Resources will acquire PVH's Warners, Olga and True & Co. businesses. The all-cash purchase price is $160M, subject to adjustment, plus an earnout based on the net sales on a portion of the acquired businesses for calendar 2024, with a maximum value of $10M. The transaction is expected to close at the end of November, subject to standard closing conditions. PVH intends to use the net proceeds from the transaction to repurchase shares of its common stock.

07:32 EST Bowman Consulting acquires Blankinship & Associates, terms undisclosed - Bowman Consulting announced the acquisition of Davis, California based Blankinship & Associates. Blankinship, an environmental sciences and engineering firm, specializes in providing water resources services, natural resource management services, permitting and compliance services, and specialized training. Established in 2000 by current president Mike Blankinship, the firm serves both public and private sector clients providing solutions to environmental and natural resources challenges that intersect the built environment and natural resources. Blankinship's staff of professionals will all become Bowman employees in connection with the acquisition. Financed with a combination of cash, seller notes, and equity, the acquisition falls within previously discussed target multiple and operating metric ranges and is expected to be immediately accretive. The company anticipates the acquisition will initially operate at an annualized net service billing run rate of approximately $3M. More detailed information on M&A activities, pipeline, and guidance updates are provided in connection with scheduled quarterly and annual communications.

07:29 EST Aclaris Therapeutics' zunsemetinib did not meet Phase 2b endpoints in arthritis - Aclaris Therapeutics announced top-line results from a Phase 2b study of zunsemetinib, an investigational oral MK2 inhibitor, in subjects with moderate to severe rheumatoid arthritis. Patients administered either the 20mg or 50mg dose did not meet the primary endpoint of ACR20 response or any of the secondary efficacy endpoints at 12 weeks, including ACR50 response, ACR70 response, and DAS28-CRP. There was no notable differentiation between zunsemetinib and placebo across any measures of efficacy at week 12. No meaningful safety findings were observed. Based on the overall program results, Aclaris will discontinue further development of the ATI-450 program, including halting enrollment of Aclaris' ongoing Phase 2a trial of zunsemetinib in psoriatic arthritis.

07:27 EST Barrick Gold makes additional investment in Hercules Silver - Barrick Gold announced that on November 10, 2023, it purchased 7,000,000 warrants to purchase common shares of Hercules Silver for total consideration of C$6,580,000. The warrants were immediately exercised at their exercise price of C$0.11 per Hercules common share. Prior to its acquisition and exercise of the warrants, Barrick owned 26,556,870 common shares of Hercules and 6,804,918 warrants, representing approximately 12.33% of the outstanding Hercules common shares on a non-diluted basis, and 15.02% on a partially-diluted basis. Barrick now owns 33,556,870 common shares and 6,804,918 warrants of Hercules, representing approximately 15.09% of the outstanding Hercules common shares on a non-diluted basis, and 17.61% on a partially-diluted basis. Barrick acquired the Hercules shares for investment purposes. Barrick may, depending on market conditions and other factors, acquire additional shares, warrants or other securities of Hercules, or dispose of some or all of the Hercules shares, warrants or other securities of Hercules that it owns at such time.

07:23 EST DMC Global appoints James O'Leary to board of directors - DMC Global announced its board of directors has elected James O'Leary as an independent director. Mr. O'Leary joins the DMC board with nearly four decades of executive leadership, finance and board-level experience, principally in the construction and industrial manufacturing industries. Mr. O'Leary previously served as chairman of publicly traded BMC Stock Holdings, Inc. prior to its merger with Builders FirstSource in 2021, after joining the board of BMC in 2014.

07:22 EST Gyre Therapeutics presents poster on hydronidone at AASLD Meeting - Gyre Therapeutics announced the presentation of a poster at the American Association for the Study of Liver Diseases' Annual Liver Meeting, November 10-14, 2023, in Boston, Massachusetts. Gyre's lead asset, Hydronidone, is currently being investigated for the treatment of Metabolic Dysfunction Associated Steatohepatitis-associated liver fibrosis in the United States. Gyre's poster presented the potential antifibrotic effects of Hydronidone and its expected mode of action in mouse hepatic fibrosis models. Key highlights from the poster presentation are below: Hydronidone significantly improved liver damage in carbon tetrachloride and 3,5-diethoxycarbonyl-1,4-dihydropyridine mouse hepatic fibrosis models and reduced the accumulation of collagen; Hydronidone inhibited the activation of hepatic stellate cells via Smad7-mediated TGF- degradation and decreased the expression of fibrosis genes in hepatic stellate cells; In a ubiquitin-proteasome dependent pathway, Hydronidone promoted the Caveolin-1 mediated TGFbetaRI degradation via Smad7; Specific knockdown of Smad7 in vivo blocked the antifibrosis effect of Hydronidone.

07:18 EST Southland Holdings awarded $77M phase of Red River Valley Water Supply Project - Southland Holdings announced that a subsidiary in its Civil segment, Oscar Renda Contracting, has been awarded a $77M contract to construct a water pipeline for the for Garrison Diversion Conservatory District in North Dakota. The scope of work includes installing approximately 8 miles of 72-inch diameter water pipeline. The water pipeline is expected to provide a sustainable water supply to a community that has experienced periods of drought. This is an initial phase of the $1B Red River Valley Water Supply Project which is anticipated to benefit nearly 50% of North Dakota's population. Construction is expected to start in Q2 2024.

07:17 EST Altus Power announces new construction facility - Altus Power announced the closing of its Blackstone Construction Facility. The facility is designed for the construction of commercial solar assets and includes capacity of $200M to fund costs including equipment, labor, interconnection as well as development fees.

07:16 EST Precision BioSciences to present data at AASLD on PBGENE-HBV for CHB - Precision BioSciences announced that the company will present late-breaking data at the American Association for the Study of Liver Diseases' or AASLD, The Liver Meeting being held in Boston, MA. The poster highlights preclinical data demonstrating PBGENE-HBV's ability to eliminate cccDNA and inactivate hepatitis B virus,HBV. DNA, meriting further investigation as a potentially curative treatment for chronic hepatitis B or CHB. The late-breaking poster, titled "Preclinical efficacy and safety of ARCUS-POL nucleases for chronic hepatitis B: a potentially curative strategy", will be on display on Monday, November 13 from 1:00 PM - 2:00 PM ET in Hall C. Based on data to be presented today in a non-human primate model of HBV, the ARCUS nuclease was well tolerated and demonstrated up to 99% viral engagement which is defined as the percent of viral DNA that is either eliminated or inactivated following treatment.. "Eliminating cccDNA and inactivating integrated HBV DNA are both essential to drive a durable loss of viral markers and achieve a functional cure for HBV," said Jeff Smith, Ph.D., Co-Founder and Chief Research Officer of Precision BioSciences. "In the data presented today, we have demonstrated the ability of our PBGENE-HBV program to durably achieve a near-complete reduction across these viral markers including HBsAg, hepatitis B e-antigen , HBV DNA and HBV RNA. We believe that these data further validate our HBV program and enable us to progress the final clinical candidate toward anticipated clinical trial application and/or investigational new drug application in 2024."

07:14 EST Verve Therapeutics falls 37% after adverse events in VERVE-101 study - Shares of Verve Therapeutics are moving lower after the company announced first human proof-of-concept data for in vivo base editing from the ongoing heart-1 Phase 1b clinical trial of VERVE-101. The company said treatment with VERVE-101 led to dose-dependent reductions of disease-causing low-density lipoprotein cholesterol in people living with heterozygous familial hypercholesterolemia. However, two patients experienced serious adverse events, which were each cardiovascular events in the context of severe underlying accelerated atherosclerotic cardiovascular disease, Verve said in a statement. One patient dosed in the 0.3 mg/kg cohort had a fatal cardiac arrest approximately five weeks after treatment due to underlying ischemic heart disease, which was determined by the investigator and independent data and safety monitoring board to be not related to treatment, according to Verve. One patient dosed in the 0.45 mg/kg cohort experienced a myocardial infarction the day after treatment. The event was considered potentially related to treatment due to the proximity to dosing. Shares of Verve Therapeutics are down 37% to $9.84 in premarket trading.

07:13 EST Neurocrine announces settlement of INGREZZA ANDA litigation - Neurocrine Biosciences announced that is has resolved all patent litigation related to lawsuits resulting from Abbreviated New Drug Applications, ANDAs, brought by companies seeking approval to market a generic version of INGREZZA prior to the expiration of applicable Neurocrine patents. As part of the resolution of these lawsuits, four companies have the right to sell generic versions of INGREZZA in the United States beginning March 1, 2038, or earlier under certain customary circumstances. "These settlements reinforce our belief in the strength of the INGREZZA intellectual property estate and provide clarity regarding INGREZZA exclusivity. As an innovation-driven biopharmaceutical company, we will continue to develop treatments for under-addressed diseases and rely on a robust patent system to protect that investment in innovation," said Darin Lippoldt, Chief Legal Office of Neurocrine Biosciences.

07:10 EST Old Republic announces sale of run-off mortgage business - Old Republic International announced that it has entered into a definitive agreement to sell its mortgage insurance business to Arch Capital Group Ltd. In this transaction, Arch U.S. MI Holdings Inc. will acquire all of the capital stock of Old Republic's wholly-owned subsidiary, RMIC Companies, Inc., and its wholly-owned subsidiaries that together comprise Old Republic's run-off mortgage insurance business. Consideration is expected to be approximately $140 million. Additionally, Old Republic expects to receive a final 4th quarter dividend of $25 million. The transaction is subject to regulatory approval and is expected to close in the first half of 2024. Commenting on the transaction, Old Republic President & CEO, Craig Smiddy, said "We are pleased to announce this definitive exit from the mortgage insurance business. Since placing this business in run-off in 2011, we have been able to preserve significant value for shareholders and we are grateful for the many years of hard work and dedication of our RMIC associates. In the last five years our run-off reserves have developed favorably, enabling us to receive over $398 million of dividends from these subsidiaries, inclusive of the $25 million expected in the 4th quarter."

07:10 EST Ipsen, Medison announce Health Canada approval for Bylvay - Ipsen and Medison Pharma announce the Health Canada approval for Bylvay for the treatment of pruritus in patients aged 6 months or older with Progressive Familial Intrahepatic Cholestasis, PFIC, a progressive and life-threatening liver disease. "Health Canada's authorization of Bylvay brings an important medicine to Canadians living with PFIC and their families," said Stewart Campbell, Executive Vice President and President of North America, Ipsen. "Bringing new medicines to new markets where unmet need exists illustrates Ipsen's mission to improve patient lives. We are pleased to work with Medison to get Bylvay to prescribers as soon as possible."

07:04 EST Old Dominion announces general rate increase of 4.9%, effective December 4 - Old Dominion Freight Line announced a general rate increase GRI of 4.9% applicable to rates established under the existing ODFL 559, 670, and 550 tariffs, effective December 4. Todd A. Polen, Old Dominion Freight Line's Vice President - Pricing Services, commented, "In line with our economic forecast and expectations for the anticipated operating environment, OD is implementing a general rate increase to ensure the continued enhancement of our high-quality service network and systems. We remain committed to providing our premium value proposition of on-time, claims-free service at a fair price as well as exceeding customer expectations and delivering on their promises. This GRI, applicable to our class tariffs, aims to partially offset rising costs associated with new real estate and expansion projects, new equipment, technology investments, and competitive employee wage and benefit packages. The overall increase is anticipated to be approximately 4.9 %. While the GRI's impact will vary based on individual shipment lanes and distances traveled, it aligns with our long-term yield management strategy. The GRI also includes nominal increases in minimum charges for intrastate, interstate, and cross-border lanes."

07:02 EST Passage Bio expects cash to fund operations into 4Q25 - Following a reallocation of resources completed in July, the company has extended its cash runway into the fourth quarter of 2025. This strategic financial management ensures that sufficient resources are available to continue delivering on meaningful clinical data from ongoing research and development efforts. The company remains steadfast in its commitment to prudent resource allocation.

06:57 EST Aecom appoints Derek Kerr to board of directors - AECOM (ACM) announced the appointment of Derek Kerr to its Board of Directors. Kerr brings to the Board extensive executive, finance and accounting expertise having previously served several leadership roles at the American Airlines Group (AAL), Inc., most recently as Vice Chair and President of American Eagle. In addition, Mr. Kerr previously served as Executive Vice President and Chief Financial Officer of American Airlines. Mr. Kerr's appointment is effective November 16, 2023, at which time he will also be appointed to the Audit Committee.

06:50 EST J.Jill appointa Maria Martinez as CHRO - J.Jill announced the appointment of Maria Martinez as its Chief Human Resources Officer, effective immediately. In this role, Martinez will lead J.Jill's human resources function and strategy, including talent acquisition and retention, corporate and retail business partners, culture and engagement, diversity, equity, and inclusion, corporate communications, and total rewards. Martinez joins J.Jill from Axogen, Inc., a publicly traded company focused on surgical solutions for peripheral nerve repair.

06:42 EST Wallbridge Mining discovers new area of gold mineralization at Grasset - Wallbridge Mining Company announced the discovery of a new area of gold mineralization at the Grasset East Flexure target area on its 100%-owned Grasset Gold property, located 15 kilometres east of the Company's flagship Fenelon Gold Project. Scattered, gold-bearing quartz veins were intersected in nine of the 19 drill holes completed. Highlights: Widespread gold-bearing quartz veining intersected in nine drill holes, so far over an approximately 1-kilometre strike length; Small visible gold grains were observed in four drill holes with assay results up to 3.20 g/t Au over 2.50 metres. Assay results are pending for the visible gold-bearing portions of two of these holes, which are similar in appearance to the intervals that have returned assays; Drill program was increased from the originally intended 5,000 metres to approx. 10,500 metres in 20 drill holes, with the final hole still being completed. This release reports final assay results from ten drill holes and results are pending for an additional ten holes, including the final one still being drilled. "Our initial drill program on the grassroots Grasset Gold property is a good start in this new, unexplored area," said Attila Pentek, Wallbridge's Vice President, Exploration. "To find widespread gold mineralization in our first drill program in this entirely overburden covered area on the eastern end of our 97-kilometre-long property along the Detour-Fenelon Gold Trend speaks volumes to the vast untested potential of this and other target areas on our over 830-square-kilometre land package."

06:40 EST Air Lease signs long-term lease contracts for 18 new Boeing 737-8 Aircraft - Air Lease (AL) announced long-term lease contracts for 18 new Boeing (BA) 737-8 aircraft with Egyptair. These new Boeing aircraft are confirmed to deliver to the airline beginning in 2025 through 2026 from ALC's order book with Boeing. This is the first deal between ALC and the Egyptian flag carrier and the first 737-8 addition to the Egyptair fleet.

06:35 EST Calibre Mining to acquire Marathon Gold for C$0.84 per share - Calibre Mining Corp. (CXBMF) and Marathon Gold Corporation (MGDPF) are pleased to announce that the Parties have entered into a definitive arrangement agreement whereby Calibre will acquire all of the issued and outstanding common shares of Marathon pursuant to a court-approved plan of arrangement. The Transaction will create an Americas-focused, high-margin, high-growth, mid-tier gold producer with estimated average annual gold production of approximately 500 koz during 2025 - 2026E. The combined company will have a strong balance sheet with a combined cash balance of $148 million and significant free cash flow generated from Calibre's existing mines. This financial strength is expected to facilitate the seamless construction of the Valentine Gold Project and a continuous flow of exciting discovery and resource-building drill results from Nicaragua, Nevada and Newfoundland & Labrador. In connection with the Transaction, Calibre has agreed to purchase on a non-brokered private placement basis 66,666,667 common shares of Marathon at C$0.60 per share for gross proceeds of C$40 million representing a 14.2% equity interest in Marathon on an issued and outstanding basis; closing is expected to be completed on November 14, 2023 and is not contingent on closing of the Transaction. Pursuant to the Transaction, Marathon shareholders will receive 0.6164 of a Calibre common share for each Marathon common share held. The Consideration implies a value of C$0.84 per Marathon common share and gross Transaction equity value consideration of C$345 million on a fully diluted in-the-money basis. This represents a premium of 32% based on spot and 61% based on Calibre's and Marathon's 20-day VWAP as at November 10, 2023. Existing shareholders of Calibre and Marathon will own approximately 66% and 34% of the combined company, respectively. Marathon will also be entitled to nominate one member to the board of directors of Calibre. In connection with the Transaction, Calibre agreed to purchase 66,666,667 common shares of Marathon at C$0.60 per share for gross proceeds of C$40 million pursuant to the Concurrent Private Placement, representing a 14.2% equity interest in Marathon on an issued and outstanding basis. Closing of the Concurrent Private Placement is expected to be completed on November 14, 2023 and is not contingent on closing of the Transaction. The Transaction will be completed pursuant to a court-approved plan of arrangement under the Canada Business Corporations Act. The Transaction will be subject to the approval of at least 66- 2/3% of the votes cast by Marathon shareholders at a special meeting of Marathon shareholders and a simple majority of disinterested shareholders The issuance of common shares by Calibre as the Consideration in connection with the Transaction is subject to the approval of a majority of the votes cast by the shareholders of Calibre at a special meeting of Calibre shareholders. In addition to shareholder approvals, the Transaction is also subject to the receipt of certain regulatory, court and Toronto Stock Exchange approvals and other closing conditions customary in transactions of this nature. The Arrangement Agreement includes, among other things, a non-solicitation covenant on the part of Marathon (subject to customary fiduciary out provisions) and a right for Calibre to match any competing offer that constitutes a superior proposal. Under certain circumstances, Calibre would be entitled to a C$17.5 million termination fee and Marathon would be entitled to a C$17.5 million reverse termination fee. Officers and directors of Calibre, along with B2Gold Corp., which hold approximately 27% of the outstanding Calibre common shares, have entered into voting support agreements pursuant to which they have agreed, among other things, to vote their Calibre common shares in favour of the Transaction. Officers and directors of Marathon which hold approximately 0.9% of the outstanding Marathon common shares, have entered into voting support agreements pursuant to which they have agreed, among other things, to vote their Marathon common shares in favour of the Transaction. Sprott Private Resource Lending II (Collector-2), LP and Sprott Resource Lending Corp. have provided a conditional waiver of certain provisions of, and defaults and events of default arising under, the amended and restated credit agreement dated January 24, 2023 between Marathon, as borrower, and Sprott relevant to or arising as a result of the Transaction. Such waivers are subject to and conditional upon the satisfaction of certain conditions prior to closing of the Transaction. Full details of the Transaction will be included in the respective management information circulars of Calibre and Marathon, expected to be mailed to shareholders in mid-December 2023. Both shareholders' meetings and closing of the Transaction are expected in January 2024.

06:31 EST Parsons included on $5B contract to revitalize Puerto Rico's power system - Parsons Corporation announced that the company was included on a multiple award indefinite-delivery, indefinite-quantity task order contract for the Puerto Rico Power System Stabilization Project by the United States Army Corps of Engineers Savannah District. The $5 billion ceiling value contract includes a base performance period of five years and represents new work for the company. Under this contract, Parsons will compete for task orders to provide temporary power generation for the stabilization of Puerto Rico's power grid, supporting the government's request for assistance and aiding residents of the island as they recover from natural disasters.

06:10 EST First Quantum Minerals provides update on Cobre Panama - First Quantum Minerals announced that its subsidiary, Minera Panama, has begun to reduce ore processing operations at the Cobre Panama mine. Cobre Panama has reduced its processing operations by ramping down one ore processing train while two remain operational. This disruption to operations is due to an illegal blockade of small boats at the mine's Punta Rincon port. The illegal actions at the port have affected the delivery of supplies for the mine's on-site power generation plant, which is necessary for full operations and for safe environmental stewardship, including operation and maintenance of the tailings management facility. In addition, the illegal actions have hindered the loading of copper concentrate onto vessels. First Quantum and MPSA respect the right to protest in a safe and lawful manner, however, the illegal actions at the port are impacting operations at Cobre Panama just as the illegal blockades by protestors in other parts of the country over the last three weeks have been impacting the daily lives of Panamanians and the Panamanian economy. The Chamber of Commerce, Industries and Agriculture of Panama estimates the cost of the protests and road blockades across the country at between $60 and $90 million per day. In response to the ongoing protests and the economic impacts, S&P, Moody's and Fitch have all taken negative credit actions for Panama in recent weeks. MPSA is taking a methodical and responsible approach to adapt its operations to these circumstances. The health, safety and well-being of the workforce, as well as the safe environmental management of the site and tailings storage facility, are central to MPSA's approach. If normal port activities do not resume, the reduction of ore processing at Cobre Panama will directly impact over 7,000 employees and contractors as well as an additional 40,000 people whose livelihood is directly associated in providing services to the mine. This is estimated to represent more than 2 percent of the Panamanian national workforce, who in turn support an estimated 100,000 Panamanians. In addition, the mine will need to significantly reduce the purchase of supplies and services that are equivalent to $20 million in weekly revenues to more than 2,000 Panamanian companies. Cobre Panama contributes approximately 5 percent of Panama's GDP and makes up 75 percent of the country's export of goods.

06:07 EST Henry Schein provides update on cybersecurity incident - The company said, "As disclosed in the Company's Current Report on Form 8-K filed on October 16, 2023, Henry Schein discovered a cybersecurity incident on October 14, 2023 that primarily affected its dental and medical distribution businesses. The Company has contained the incident, restored most of the business-critical systems it proactively took offline in response to the situation, and is making significant progress towards resuming normal-course operations. On November 2, 2023, the Company filed a Form 12b-25 with the SEC and expects to file its Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2023 before the end of November 2023. The Company also expects to file an insurance claim in 2024 related to this incident. We expect the claim will be covered under its cyber insurance policy, although final resolution is subject to insurer approval. This policy has a $60 million after-tax claim limit after a $5 million retention, and any recovery from the claim will likely not be recognized until late 2024."

05:31 EST Emirates orders 90 Boeing 777X airplanes - Boeing and Emirates announced that the world's largest 777 operator has placed an order for 90 777X airplanes, including 55 777-9 and 35 777-8 jets. The new order, which increases Emirates' 777X family backlog to 205 planes, was announced during the Dubai Airshow at a signing event attended by His Highness Sheikh Ahmed bin Saeed Al Maktoum, chairman and CEO, Emirates Airline and Group; and Stan Deal, president and CEO of Boeing Commercial Airplanes.

05:25 EST Bombardier Defense delivers seventh aircraft for Saab - Bombardier Defense announced the seventh Global aircraft delivery to defense and security company Saab, ready to be transformed into Saab's Airborne Early Warning and Control, or AEW&C, solution known as GlobalEye. This new delivery comes as the two companies attend the Dubai Air Show 2023, where Bombardier presents its versatile Global and Challenger business jets to the Middle East market, and Saab showcases the leading capability of GlobalEye. Bombardier's latest Global aircraft delivery is destined to join the Swedish Air Force and will be Saab's second GlobalEye aircraft to join Sweden's military fleet. The seven aircraft delivered by Bombardier to the GlobalEye program highlight a successful collaboration and echo Bombardier's thriving, long-standing reputation manufacturing specialized aircraft for the defense industry.

05:20 EST Sasol announces Sipho Nkosi steps down as chairman, non-executive director - Shareholders are advised in terms of paragraph 3.59 of the JSE Listings Requirements that Sipho Nkosi has stepped down as chairman and non-executive director of Sasol. Nkosi came to the conclusion that, while he was comfortable that he would be able to comply with the conflict of interest requirements of the Companies Act, 2008 and of the company, he was concerned that some of his business interests may be perceived to place him in conflict with the interests of Sasol. The board has appointed Stephen Westwell, currently non-executive and lead independent director, as pro tem chairman of the board of Sasol, with effect from November 11. The nomination and governance committee will in due course nominate a successor for the role of chairman in line with its formal succession plan.

05:12 EST Boeing reports SunExpress to purchase up to 90 737 MAX jets - Boeing and SunExpress, a joint venture of Turkish Airlines and Lufthansa, announced the airline has again selected the 737 MAX. With a commitment to purchase up to 90 fuel-efficient single-aisle Boeing jets, announced at the Dubai Airshow, Turkiye's leisure carrier will more than double its fleet into the next decade. The agreement includes 28 737-8 and 17 737-10 models, with the opportunity for up to 45 additional 737 MAX airplanes.

05:07 EST Brookfield Asset Management opens new office in Frankfurt - Brookfield Asset Management announced the opening of its new Frankfurt office. The new office reinforces Brookfield's conviction in Germany and enables it to be closer to its investors, portfolio companies and investment opportunities across the German-speaking region. Brookfield has been actively investing in Germany since 2013. Through its operations, Brookfield employs over 4,000 people in Germany.